Moroctocog alfa (AF -CC) 
3082B2 -313-WW –(B1831001) 
Final Amendm ent 
10,02 October 2015
Page 1AN OPEN- LABEL STUDY TO EVALU ATE PROPHYLAXIS TREATMENT, AND 
TO CHARACTERIZE THE EFFICACY, SAFETY, AN D PHARMACOKINETICS 
OF B -DOMAIN DELETED RECOM BINANT FACTOR VIII ALBUMIN FREE 
(MOROCTOCOG ALFA [AF -CC]) IN CHILDREN WITH HEMOPHILIA A
Date of Original Protoco l: 09 Mar 2007
Amendment 1: 12 Jun 2007
Amendment 2: 27 Aug 2007
Amendment 3: 22 Jan 2009
Amendment 4: 15 Sep 2009
Amendment 5: 20 Jul 2010
Amendment 6: 10 Mar 2011
Amendment 7: 31 Aug 2011
Amendment 8: [ADDRESS_280216] 2012
Amendment 9: 29 Jan 2013
Amendment 10: [ADDRESS_280217] 2015
Sponsor: Wyeth Pharmaceuticals Inc. acting through its division Wy eth Research, a 
[COMPANY_007] Company
This amendment incorporates all revisions to date, including amendments made at the 
request of country  health authorities, institutional review boards/ethics committees 
(IRBs/ECs), etc. 

Moroctocog alfa (AF -CC) 
3082B2 -313-WW –(B1831001) 
Final Amendm ent 
10,02 October 2015
Page 2TABLE OF CONTENTS
1. DI SCLOSURE STATEMENT ..............................................................................................7
2. CONTACTS ..........................................................................................................................7
3. ABBREVI ATIONS ...............................................................................................................7
4. DEFI NITIONS .......................................................................................................................9
5. SYNOPSI S
...........................................................................................................................16
6. STUDY OVERVIEW ..........................................................................................................20
7. STUDY FL OWCHART 1 : ROUTINE PROPHYLAXI S (RP) COHORT STUDY 
PROCEDURES ...................................................................................................................21
8. STUDY FL OWCHART 2 : PHARMACOKI NETI C AS SESSMENT VI SIT 2 
(DAY 1)
..............................................................................................................................23
9. BACKGROUND INFORM ATION AND RATIONALE ...................................................24
9.1. The History  of ReFacto and Moroctocog alfa (AF
-CC).........................................24
9.2. Manufacturing Changes for Moroctocog alfa (AF
-CC)..........................................24
9.3. Clinical Experience With Moroctocog alfa (AF -CC).............................................25
9.4. Rationale for the Current Moroctocog alfa (AF
-CC) Study  
(3082B2-313- WW) ................................ ................................ ................................ ....[ADDRESS_280218] Participation
....................................................29
11.3. Approximate Duration of Stu dy............................................................................29
11.4. Approximate Number of Subjects .........................................................................30
12. SEL ECTION OF SUB JECTS................................ ................................ ............................ 30
12.1. I nclusion Criteria ...................................................................................................30
12.2. Exclusion Criteria
..................................................................................................32
12.3. L ife Sty le Guidelines .............................................................................................33
12.4. Sponsor’s Qualified Medical Personnel ................................................................33
13. PRI OR TREATMENT .......................................................................................................34
14. CONCOMI TANT TREA TMEN T
................................ ................................ ..................... 34
14.1. Prohibited ..............................................................................................................34

Moroctocog alfa (AF -CC) 
3082B2 -313-WW –(B1831001) 
Final Amendm ent 
10,02 October 2015
Page 314.2. Permitted ...............................................................................................................34
15. PROCEDURES ..................................................................................................................35
15.1. Study  Procedures for RP Cohort ...........................................................................35
15.1.1. Consent/Assent
.........................................................................................35
15.1.2. Pay ment of Subjects .................................................................................35
15.1.3. Study  Visit 1 (Screening Visit) -RP Cohort ............................................36
15.1.4. Screening Period Activities and Ra
ndomization - RP Cohort ..................37
15.1.5. Study  Visit 2 (Day  1) -
Segment 1 - RP Cohort ................................ .......38
[IP_ADDRESS]. Pharmacokinetic Assessment (if App licable) - Segment [ADDRESS_280219] Cohort ...........................................................................38
[IP_ADDRESS]. Study  Drug Dispensed -RP Cohort ........................................[ADDRESS_280220] Activities Between Suc cessive Study  Visits (Visit 2 
Through Visit 11), and Activities of Study  Contacts 4, 6, 8, and 10 -
Segment 1 - RP Cohort ................................ ................................ .................... 39
15.1.7. Study  Visits 3, 5, 7, and 9 (Study  Months 1, 3, 6, and 9) –
Segment 1 -RP Cohort ................................ ................................ .................... 40
15.1.8. Study  Visit 11 (Study  Month 12) - RP Cohort ................................ ......... 41
[IP_ADDRESS]. Start of Segment 2 - RP Cohort ...............................................42
[IP_ADDRESS]. Study  Drug Dispensed –
Segment [ADDRESS_280221] Activities Between Successive Study  Visits (Visit 11 
Thro ugh Visit 19), and Activities of Study  Contacts 12, 14, 16, and 18 -
Segment 2 - RP Cohort ................................ ................................ .................... 43
15.1.10. Study  Visits 13, 15, and 17 (Months 15, 18, and 21) - Segment 2 -
RP Cohort .........................................................................................................43
15.1.11. Final Study  Visit (Visit 19, Month 24) -
Segment 2 – RP Cohort ......... [ADDRESS_280222] (Visit 20) – RP Cohort ...........................................[ADDRESS_280223] ARTI CLE AND ADMINISTRATION ................................ ................................ ...50

Moroctocog alfa (AF -CC) 
3082B2 -313-WW –(B1831001) 
Final Amendm ent 
10,02 October 2015
Page 416.1. Moroctocog alfa (AF- CC) Administration for Pharmacokinetic Assessment ......50
16.2. Moroctocog alfa (AF
-CC) Administration for Rechallenge .................................50
16.3. Moroctocog alfa (AF
-CC) Administration for Hemophilia A Treatment .............50
16.3.1. Moroctocog alfa (AF
-CC) Administration for On- Demand 
Treatment of Breakthrough Bleeds ..................................................................51
16.3.2. Moroctocog alfa (AF
-CC) Administrat ion for Prophy laxis .....................[ADDRESS_280224] Compliance ...............................................................................................53
17. SAFETY ............................................................................................................................53
17.1. Factor VIII Inhibitors ............................................................................................54
17.2. Antibodies to Moroctocog a lfa (AF
-CC) Components .........................................[ADDRESS_280225] Populations in the Analy sis of Study  Variables .......................................62
22.4.1. Safet y Variables ........................................................................................62
22.4.2. Efficacy
 Variables ................................ ................................ .................... 62

Moroctocog alfa (AF -CC) 
3082B2 -313-WW –(B1831001) 
Final Amendm ent 
10,[ADDRESS_280226] Findings........................................................................................68
26.5. Serious Adverse Events .........................................................................................69
26.5.1. Protocol
-Specified Seri ous Adverse Events .............................................70
26.5.2. Potential Cases of Drug -Induced Liver Injury  (Potential Hy ’s Law 
Cases) ...............................................................................................................70
26.6. Hospi[INVESTIGATOR_059] ......................................................................................................71
26.7. Severity  Assessment ..............................................................................................72
26.8. Causality  Assessment ............................................................................................72
26.9. Exposure During Pregnancy ................................ ................................ .................. 73
26.10. Occupational Exposure .......................................................................................74
26.11. Withdrawal Due to Adverse Events (See Also Section [ADDRESS_280227] 
Discontinuation or Withdrawal) ................................................................................74
26.12. Eliciting Adverse Event Information ..................................................................74
26.13. Reporting Requirements ......................................................................................75
26.13.1. Serious Adverse Event Reporting Requirements ...................................75
26.13.2. Non
-Serious Adverse Event Reporting Requirements ...........................75
26.13.3. Sponsor’s Reporting Requirements to Regulatory  Authorities ..............75

Moroctocog alfa (AF -CC) 
3082B2 -313-WW –(B1831001) 
Final Amendm ent 
10,[ADDRESS_280228]/Ethics Comm ittee......................................................[ADDRESS_280229] INJURY ...........................................................................................................80
34. PRESTUDY DOCUMEN TATION ...................................................................................80
35. RECORDS RETENTIO N
..................................................................................................81
36. SAMPLE RETENTION ....................................................................................................81
37. CLINI CAL  STUDY R EPORT ..........................................................................................81
38. PUBLICATION OF S TUDY RESUL TS..........................................................................81
38.1. Communication of Results by  [CONTACT_4618] ....................................................................81
38.2. Publications by  [CONTACT_4718] ................................................................................82
39. REFERENCES ..................................................................................................................83
40. APPENDI
CES ...................................................................................................................86
APPENDICES
Appendix 1. Guidelines for On
-Demand Treatment With Moroctocog alfa (AF -CC)............86

Moroctocog alfa (AF -CC) 
3082B2 -313-WW –(B1831001) 
Final Amendm ent 
10,02 October 2015
Page 71.DISCLOSURE STATEMENT
Restricted Distribution of Documents
This document contains information that is confidential and proprietary  to the Sponsor.  This 
information is being provided to y ou solel y for the purpose of evaluating and/or conducting a 
clinical study  for the 
Sponsor.  You may  disclose the contents of this document only  to study  
personnel under your supervision, institutional review bo ards (I RBs)/independent ethics 
committees (IECs), or duly  authorized representatives of regulatory  agencies for this purpose 
under the condition that they  maintain confidentiality .  The contents of this document may  
not be used in an y other clinical study, disclosed to any  other person or entity , or published 
without the prior written permission of the Sponsor.  The foregoing shall not apply  to 
disclosure required b y any regulations; however, you will give prompt notice to the Sponsor 
of an y such disclosure .  All other nonpublic information provided by  [CONTACT_941] S ponsor, as well as 
any information that may be added to this document, also is confidential and proprietary  to 
the Sponsor and must be kept in confidence in the same manner as the contents of this 
document.
2.CONTACTS
NOTE: Emergency  Contact, Regional Contact [CONTACT_232237].
3.ABBREVIATIONS
Abbreviation Term
ABR Annualized bleed rate
AE Adverse event
ALT Alanine aminotransferase
ANOVA Anal ysis of variance
AST Aspartate aminotransferase 
AUC Area under the curve to infinity
AUC t Area under the curve to last measurable concentration
AUMC Area under moment curve
BDDrFVIII B-Domain deleted recombinant factor VIII, commerciall y 
available a s ReFactoor as ,the investigational drug 
moroctocog alfa (AF -CC), (marketed in certain regions of the 
world as Xy ntha)
BU Bethesda unit
CFR Code of Federal Regulations
CHO Chinese hamster ovary cells (host cell line for moroctocog alfa 
[AF-CC] produc tion)
CL Clearance
C0.5 hr FVIII:C at 0.[ADDRESS_280230] FVIII:C observed at a specified time (t)

Moroctocog alfa (AF -CC) 
3082B2 -313-WW –(B1831001) 
Final Amendm ent 
10,02 October 2015
Page 8Abbreviation Term
E-DMC External -Data Monitoring Committee
eCRF Electronic case re port form
ED Exposure day
EIU Exposure in- utero
ELISA Enzy me-linked immunosorbent assay
EMA European Medicines Agency
EDP Exposure during pregnancy
FDA [LOCATION_002] Food and Drug Administration
FVIII Factor VIII
FVIII:C Factor VIII activit y in pla sma
GCP Good clinical practice
HIV Human immunodeficiency virus
HSA Human serum albumin
IEC Independent ethics committee
IND Investigational new drug application
INR International normalized ratio
IRB Institutional review board
ITT Intent to treat
IV Intravenous
IVIG Intravenous immunoglobulin
LETE Less than expected therapeutic effect
LLN Lower limit of normal
mITT Modified intent to treat
moroctocog alfa 
(AF-CC)B Domain Deleted Recombinant FVIII, Albumin Free
MRT Mean residence time
NSAID Nonsteroidal anti -inflammatory  drug
OD On-demand
OS One-stage FVIII activity  assay
pdFVIII Plasma -derived FVIII
PK Pharmacokinetics
PT Prothrombin time
PTP Previously  treated patient
PUP Previously  untreated patient
rFVIII Recombinant FVIII
RP Routine prophy laxis
SAE Serious adverse event
SD Standard deviation
t½ Terminal phase half -life
ULN Upper limit of normal
Vss Steady  state volume of distribution
WHO World Health Organization

Moroctocog alfa (AF -CC) 
3082B2 -313-WW –(B1831001) 
Final Amendm ent 
10,02 October 2015
Page 94.DEFINITIONS
Term Definition
Anti- CHO antibodies Antibodie s to proteins derived from the Chinese hamster ovary 
(CHO) host cell line used to produce moroctocog alfa (AF -CC).
Anti- FVIII antibodies Neutralizing and nonneutralizing antibodies to FVIII.
Anti- TN8.2 
antibodiesAntibodies to the affinity ligand (TN8. 2) used during the 
moroctocog alfa (AF -CC) purification process.
Bleeding epi[INVESTIGATOR_232204] (bleeding) caused b y injury  or occurring 
spontaneously  at [ADDRESS_280231]/caregiver’s report in the Subj ect Diary  
(or b y the investigator in the subject’s source document). A 
subject/caregiver’s report does not need to be independently 
verified.
Bleeding
(breakthrough)Bleeding occurring since last routine prophy lactic dose of 
FVIII therapy . 
Bleeding 
(spontaneous )Bleeding occurring in the absence of known injury or an y 
antecedent cause.
Bleeding
(traumatic)Bleeding occurring because of an injury  or activity  that would lead 
to a bleed in a hemophilic patient (for example, exercise).
Caregiver For t he purpose of this protocol, a person who provides for and/or 
oversees the general care of the subject.  The person may  
administer study  drug to the subject for home use and performs 
many  activities required by  [CONTACT_232238], but not limited 
to, reporting of bleeds and study  drug usage.  The person could be 
a parent, other family member, or legal acceptable representative. 
Case report form A printed or electronic document designed to record all the 
protocol -required information to be reported to the Sponsor on 
each stud y subject.
Central laboratory The reference laboratory  designated by  [CONTACT_941] S ponsor to anal yze 
selected samples as described in this protocol. There may  be 
multiple central laboratories.

Moroctocog alfa (AF -CC) 
3082B2 -313-WW –(B1831001) 
Final Amendm ent 
10,[ADDRESS_280232] and who is not withdrawn early .
Designee A person with the appropriate qualifications to whom a task has 
been delegated without relinquishing responsibilities of the 
specified person/role. 
Exposure day  (ED) Any day during which the subject receives stud y drug. One (1), or 
more than 1, dose of study drug may  be administered on a single 
ED.
FVIII inhibitor
(confirmed)A neutral izing antibody  to FVIII with a titer of ≥0.6 BU/mL  in a 
sample assay ed at the central laboratory  using the Nijmegen assay .
FVIII inhibitor
(de novo)Development of a confirmed FVIII inhibitor during the course of 
the study  in a subject with no prior clinical history of FVIII 
inhibitor, or prior history of measurable inhibitor activity  by 
[CONTACT_232239].
FVIII inhibitor
(history  of)A history  of FVIII inhibitor (clinical or laboratory -based 
assessment).  For laboratory -based assessments, any  measured 
Bethesda inhibitor titer of ≥0.6 BU/mL , regardless of the 
laboratory  normal range, or any  measured Bethesda inhibitor titer 
greater than the ULN for the laboratory  performing the assay .
FVIII replacement 
productA concentra ted recombinant or plasma -derived formulation of the 
Factor VIII protein made for use in the treatment and prevention 
of bleeding in patients with hemophilia A (for the purposes of this 
protocol fresh frozen plasma, cry oprecipi[INVESTIGATOR_232205]).
Hematology  panel Measurement of the complete blood count, which includes 
hemoglobin, hematocrit, white blood cell count and differential, 
red blood cell and platelet count.
Incremental recovery The IU/dL of FVIII:C inc rease per IU/kg of FVIII infusion.
Independent ethics 
committee (IEC)Throughout this document, the term ethics committee refers to all 
appropriate and properl y constituted committees or boards 
recognized to be the appropriate regulatory  agencies for approving 
clinical studies. These include independent ethics committees and 
institutional review boards.

Moroctocog alfa (AF -CC) 
3082B2 -313-WW –(B1831001) 
Final Amendm ent 
10,02 October 2015
Page 11Term Definition
Intent -to-treat 
populationThe intent -to-treat population consists of subjects who sign the 
consent/assent form.   (Screen failures are excluded) .
Investigator A person, with the appropriate qualifications, responsible for the 
conduct of the stud y at a study site. 
Lack of efficacy Failure of expected pharmacologic action or therapeutic benefit.
Less than expected 
therapeutic effect, 
LETE (on- demand )Less than Expected Therapeutic Effect (LETE) occurs in the 
on-demand setting if the subject/caregiver records 2 successive 
“No Response” ratings after [ADDRESS_280233], 
LETE (proph ylaxis)Less than Expected Therapeutic Effect (LETE) occurs in the 
prophylaxis setting if there is a spontaneous bleed within 48 hours 
(
≤48 hours) after a regularly  scheduled prophy lactic dose of study  
drug (which was not used to treat a bleed) in the absence of 
confounding factors as described in this protocol.
Less than expected 
therapeutic effect, 
LETE (low rec overy )Lower than expected recovery  of FVIII in the opi[INVESTIGATOR_232206]. 
Medical records Legal documentation (written or electronic) of a patie nt's medical 
history , current illness, diagnosis, treatments, and/or other medical 
data that is maintained by  [CONTACT_093]. For the purposes of 
this study , these can serve as source documents.
Modified 
intent -to-treat 
population The modified intent -to-treat population consists of subjects who 
receive at least 1 dose of study  drug (moroctocog alfa [AF -CC]).
Monitor A person, with the appropriate qualifications and assigned by  [CONTACT_429], to oversee the progress of a study , and to ensure that it is
conducted, recorded, and reported in accordance with the protocol 
and other applicable requirements. 
On-demand (OD) 
SubjectA study  subject that practices on -demand therap y with moroctocog 
alfa (AF -CC) for the first segment of the study , followed by  
[CONTACT_232240].

Moroctocog alfa (AF -CC) 
3082B2 -313-WW –(B1831001) 
Final Amendm ent 
10,02 October 2015
Page 12Term Definition
On-demand treatment Treatment of hemorrhages, as needed, b y administering an 
unscheduled bolus infusion of study drug to stop bleeding and 
control hemostasis.
Patient For the purposes of this protocol, a person with hemophilia A. 
Previously  treated 
patients (PTPs)Patients who have received FVIII replacement therap y. For the 
purposes of this study , PTPs are those who have accrued 
[ADDRESS_280234].
Previously  untreated 
patients (PUPs)Patients who have not received an y FV III replacement therap y or 
any blood products.
Prophy laxis FVIII replacement therapy administered at a routine interval such 
as every  other day , for a prolonged period of time, to prevent 
occurrence of s pontaneous musculoskeletal bleeding epi[INVESTIGATOR_1841].
Regimen A Study  drug prophy laxis regimen of 45 5 IU/kg, administered 
twice per week.  The interval between prophy lactic infusions 
should be 3 to 4 day s, and should not exceed 4 days. 
Regimen B Study  drug proph ylaxis regimen of 25 5 IU/kg, administered 
every  other day .  The interval between proph ylactic infusions 
should be approximatel y 48 hours (eg, an appropriate dosing 
schedule for Regimen B is as follows Monday , Wednesday , 
Friday , Sunday , Tuesday, Thur sday, Saturday , Monday …etc). 
Regimen escalation During proph ylaxis, criteria for proph ylaxis regimen escalation are 
the occurrence, over a 4 -week period (and in the absence of a 
confirmed FVIII inhibitor), of (a) 2 or more spontaneous bleeds 
into a majo r joint and/or target joint, OR(b) 3 or more 
spontaneous bleeds (consisting of joint bleeds and/or significant
soft tissue/muscle or other site bleeds). If either criterion is met, 
the subject will be escalated to a more intense prophy laxis regimen 
of 45 ±5 IU/kg, administered every  other day .  Subjects who meet 
dose escalation criteria while on this more intensive regimen may  
dose escalate to a higher intensity  regimen designated by  [CONTACT_1275].  Significant spontaneous bleeds are defined as those 
that lead to a transient or persistent loss of function.

Moroctocog alfa (AF -CC) 
3082B2 -313-WW –(B1831001) 
Final Amendm ent 
10,02 October 2015
Page 13Term Definition
Regulation The term regulation refers to all applicable regulations, laws, and 
guidelines.  The regulations may  be international, national, or local 
and may  include but are not limited to the Code o f Federal 
Regulations; the European Clinical Trials Directive; the Good 
Clinical Practice: Consolidated Guideline (Canada); the 
International Conference on Harmonisation Guideline for Good 
Clinical Practice; the Pharmaceutical Affairs Law and Good 
Clinical Practice (Japan); the Therapeutic Goods Administration 
Annotated International Conference on Harmonisation Guidelines 
(Australia); the World Medical Association Declaration of 
Helsinki: Ethical Principles for Medical Research Involving 
Human Subjects; and other regulations if they  apply .
Regulatory  agency The term regulatory agency refers to all health and regulatory  
agencies with oversight responsibility  for the study .  These may  be 
international, national, or local and may  include but are not limited 
to the Australian Therapeutic Goods Administration (TGA); the 
Canadian Health Products and Food Branch (HPFB); the European 
Medicines Agency  (EMA); the Japanese Ministry  of Health, 
Labor, and Welfare (MHL W); the Japanese Pharmaceuticals and 
Medical Devices Agency (PMDA); the US Food and Drug 
Administration (FDA); and other regulatory  agencies if they  
apply .
Routine Prophy laxis 
(RP) SubjectA study  subject that practices routine prophy laxis therapy  with 
moroctocog alfa (AF -CC) according to the randomly  assigned 
regimens for the first and second segments of the study .
Screening period Interval starting from the signing of the informed consent/assent 
(study  visit 1) and extending up to study  day 1 (study  visit 2).  
There are up to approximately  35 screening day s.
Serum chemistry Measurement of sodium, potassium, chloride, CO 2(serum 
bicarbonate), ALT, AST, calcium, glucose, creatinine, blood urea 
nitrogen (BUN), (total) bilirubin, phosphorus, alkaline 
phosphatase, total protein, amy lase, cholesterol and alb umin.
Source 
documentationOriginal documents, data, and/or records (eg, patient medical 
record, Subject Diary ).
Sponsor The term Sponsor refers but is not limited to the sponsors listed in 
the front of this document and an y contract research organization 
that is being used for the study .

Moroctocog alfa (AF -CC) 
3082B2 -313-WW –(B1831001) 
Final Amendm ent 
10,[ADDRESS_280235] article, moroctocog alfa (AF- CC) (marketed in certain regions 
of the world as Xy ntha®) , and the solutions and materials 
accompan ying moroctocog alfa (AF- CC) preparations.
Study  start date Date that the first stud y subject provides informed consent/assent.
Study  end date Date of Final Study  Contact [CONTACT_232241].
Study  Reference 
Manual(s) A general term describing instructions and materials for 
completing study activities. Supplied to study  sites by  [CONTACT_941] S ponsor 
in addition to this protocol.
Study  Site The location(s) where study -related activities are actually  
conducted.
Subject A participant in a clinical study .  A subject may  be healthy  or have 
adisease.   For obtaining informed consent, this term also includes 
alegall y acceptable representative where applicable. 
Subject Diary Collection of forms (or electronic data) filled out directly  by [CONTACT_232242]. 
The forms will collect information on infusions, bleeding and 
bleeding response to study  drug, adverse events and other required 
study  information. The diary  is turned in at each study  visit and 
replaced with a new diary . For the purposes of th is study , can 
serve as source documents.
Target joint A major joint (eg, hip, elbow, shoulder, knee, ankle) into which 
repeated bleeding occurs (frequency of 3 or more bleeding 
epi[INVESTIGATOR_17767] 6 months), and/or clinical signs and/or sy mptoms of 
underly ing target joint damage (s ynovitis, persistent swelling, 
effusion, limitation of range of motion, eg an y objective limitation 
or joint held in flexion or “frozen”).
Test article Any drug, comparator, placebo, nutritional product, dietary  
supplement, herbal p roduct, vaccine, biologic product, or device 
used in the Sponsor’s studies.  For test article accountability , this 
term applies to such articles when they  are required by  [CONTACT_232243] (shipped) by  [CONTACT_1034] (including diluents 
such as steril e water for injection). 
Time on study Time from signing the informed consent/assent to last study  
contact [CONTACT_232244].
TN8.2 The affinit y ligand used during the moroctocog alfa (AF -CC) 
purification process.

Moroctocog alfa (AF -CC) 
3082B2 -313-WW –(B1831001) 
Final Amendm ent 
10,[ADDRESS_280236] receives study drug.  The 
period starts at study  visit 2 (day  1) and ends at the Final Study  
Visit (visit 15, month [ADDRESS_280237] is enrolled).
Washout The time between the last dose of FVIII replacement product or 
blood product (eg, fresh frozen plasma, cryoprecipi[INVESTIGATOR_047], blood) and 
the collection of FVIII activity  or other laboratory  information. 
For this study , the minimal washout time is 72 hours. The intent 
of the washout is to allow complete clearance of previous FVIII 
replacement therap y from the blood.

Moroctocog alfa (AF -CC) 
3082B2 -313-WW –(B1831001) 
Final Amendm ent 
10,02 October 2015
Page 165.SYNOPSIS
Study Title: An Open -Label Study to Evaluate Prophylaxis Treatment, and to Characterize the Efficacy, 
Safety, and Pharmacokinetics of B -Domain Deleted Recombinant Factor VIII Albumin Free (moroctocog 
alfa [AF -CC]) in Children With Hemophilia A
Protocol 
Number3082B2 -313-WW –Amendment 10 Phase 3 Type Interventional
Condition/Disease: Hem ophilia A
Approxim ate
Number of Subjects [ADDRESS_280238] 
Participation26 months (RP Subject s)
20 or 26 mo nths (OD 
Subject s) Cohort Closed
Number of Study 
CentersApproximately 40
globallyDuration of Study 8 years ;includes [ADDRESS_280239] enrolled
Rationale: While prophylaxis therapy with factor VIII (FVIII) products has increasingly been prescribed 
worldwide, direct clinical information on optimal prophylaxis dosing strategies is limited.  Therefore, this 
study will dir ectly evaluate the efficacy of moroctocog alfa (AF -CC), a recombinant FVIII product in 
clinical development, prophylaxis to reduce bleed rates relative to moroctocog alfa (AF -CC) on -demand 
therapy, and will compare the clinical outcomes of a high -versus low -frequency prophylaxis dosing regimen 
in arandomized crossover design.  In addition, younger hemophilia A patients may respond differently to 
FVIII therapy compared w ith older children and adults.  Thus, it is important to continue to characterize the 
pharmacokinetics (PK) of moroctocog alfa (AF -CC) in patients with hemophilia . In addition to the FVIII 
PK data follow ingmoroctocog alfa (AF -CC) administration already collected inthis study from children 
younger than 6 years of age , additional opportunit y for PK data collection is being provided .  Furthermore, 
the efficacy and safety of moroctocog alfa (AF -CC) during routine prophylaxis treatment will be described 
in these young patients.
Enrollment into the on -demand (OD) cohort has been closed .  To dat e, there aredata indicating that 
prophylaxis therapy controls bleeding epi[INVESTIGATOR_232207]-demand therapy .  Because of availability of 
FVIII:C PK data follow ing Xyntha administration in children with the Food and Drug Administration ( FDA )
approval, en rollment into the PK assessment is optional.
Given that prophylaxis has replaced OD therapy as 
thepreferred standard of medical care, the study will continue enrollment into the routine prophylaxis (RP) 
cohort to assess the effect of a high (25 IU/kg eve ry other day) versus low (45 IU/kg twice per 
week) -frequency dosing schedule on the efficacy of moroctocog alfa (AF -CC) prophylaxis for male subjects 
6 months to <16years of age.
Prim ary Objective:
To demonstrate that moroctocog alfa (AF -CC) prophylaxi s reduces annualized bleeding rates (ABRs) 
relative to on -demand therapy.   Enrollment into the on -demand (OD) cohort has been closed .
Secondary Objectives:
To assess the effect of a high ( 25 IU/kg every other day )
-versus low  (45 IU/kg twice per week) -frequency 
dosing schedule on the efficacy of moroctocog alfa (AF -CC) prophylaxis.
Tocontinue to characterize the PK of FVIII after moroctocog alfa (AF -CC) administration in children 
6months to <16years of age.
To describe moroctocog alfa (AF -CC) efficacy and safety in children, including characterization of the 
incidence of “less than expected therapeutic effect”.
Design: This [ADDRESS_280240] been twocohorts 
enrolled into the study; one in whic h the subject practices on -demand therapy for the first segment of the 
study, followed by [CONTACT_232245], and, another cohort in which the subject 
practices routine prophylaxis for both segments.  Study subjects will be hereafte r referred to by [CONTACT_232246] (AF -CC) 
3082B2 -313-WW –(B1831001) 
Final Amendm ent 
10,02 October 2015
Page 17segment 1 treatment modality: on -demand (OD) subjects and routine prophylaxis (RP) subjects.   Enrollment 
forthe OD cohort has been closed.  Enrollment for the RP cohort is ongoing.
All RP 
subjects will practice prophylaxis with mor octocog alfa (AF -CC) study drug according to oneof two
randomly assigned moroctocog alfa (AF -CC) regimens, each delivering approximately 90 IU/kg/ week, but 
differing in dosing schedule .  Randomization will be stratified by [CONTACT_232247] A severity: FVIII act ivity 
<1% or 1-2% (central laboratory screening result).   Each segment will be [ADDRESS_280241] 
segment , subjects w ill be randomly assigned to Regimen A: 45 5 IU/kg, administered twice perweek or 
Regimen B: 25 5 IU/kg, administered every other day.
After completion of the first segm ent, all subjects will cross over to the second prophylactic regimen for 
segment [ADDRESS_280242]’s treatment will be escalated to a higher intensity prophylaxis regimen 
comprised of the most intensive components of both regimens A and B (45 5 IU/kg, administe red every 
other day) if criteria justifying regimen escalation are met: over a 4 -week period, the occurrence of 2 or 
more spontaneous joint bleeds or the occurrence of 3 or more spontaneous bleeds (consisting of joint bleeds, 
and/or significant soft tissue /muscle or other site bleeds).  Subjects who meet dose escalation criteria while 
on this more intensive regimen may dose escalate to a higher intensity regimen designated by [CONTACT_1275].  During prophylaxis, subjects will also use moroctocog alfa (AF -CC), as needed, for the 
treatment of bleeds (ie, on -demand), should they occur.
Clinical and laboratory examinations, including assessments for FVIII inhibitor development, will be 
conducted during the course of the study.
Moroctocog alfa (AF -CC) efficac y and safety will be assessed over the entire treatment period.
A subset of subjects may participate in assessments for FVIII PK characterization after administration of 
moroctocog alfa (AF -CC).  This subset of subjects will undergo a baseline PK assessme nt, receiving a single 
open -label dose of moroctocog alfa (AF -CC) (50 5 IU/kg , rounded to the closest complete vial ) with blood 
sampled for FVIII activity measurements before and at 0.5, 8, 24, 28 (optional), and 32 hours after the start 
of infusion. 
Main Inclusion Criteria: Males 6 months to <16 years of age at the time of screening visit with 
moderately severe to severe hemophilia A (FVIII activity 2%), w ith previous FVIII replacement therapy 
experience ( 20 exposure days).
Main Exclusion Criteri a:Current or history of FVIII inhibitor.
Concom itant Treatment: Regular medication, other than FVIII concentrates, may continue unchanged.
Test Articles(s) and Administration: Moroctocog alfa (AF -CC) study drug; single 50 5 IU/kg (rounded to 
closest complete vial) intravenous infusions administered for PK assessment; either 4 5 IU/kg twice per w eek 
or 25IU/kg every other day for prophylaxis treatment (or according to investigator prescription in the event 
that escalation criteria are met while the subj ect is practicing the initial protocol -defined escalated regimen).
Safety Evaluation: Safety variables will be as follows: the incidence of adverse events (by [CONTACT_232248] (AF -CC)); the incidence of FVIII inhibitor deve lopm ent, development of 
antibodies to moroctocog alfa (AF -CC), CHO cell proteins, and TN8.2.  Laboratory -based assessments for 
FVIII inhibitor will be conducted at intervals of approximately every 3 months.
Efficacy Evaluation: Efficacy variables will in clude ABR, number of moroctocog alfa (AF -CC) infusions 
per bleed, response of bleed to moroctocog alfa (AF -CC) treatment (4 -point scale of assessment), time 

Moroctocog alfa (AF -CC) 
3082B2 -313-WW –(B1831001) 
Final Amendm ent 
10,02 October 2015
Page 18interval betw een bleed onset and prior moroctocog alfa (AF -CC) routine prophylaxis dose, incidence of 
prophylaxis regimen escalation, incidence of less than expected therapeutic effect (LETE), consumption of 
moroctocog alfa (AF -CC), and compliance with assigned prophylaxis regimen.  All subjective assessments 
will be provided by [CONTACT_232249].
Pharm acokinetics: FVIII activity in plasma (FVIII:C) will be analyzed using noncompartmental methods 
and the following PK parameters calculated for each subject: FVIII:C 0.5 hours after the beginning of the 
infusion (C 0.5hr), incremental recovery, area-under -the FVIII:C -time curve to the last measureable FVIII:C 
(AUC t) and AUC extrapolated to infinity (AUC ∞), terminal phase half -life (t ½), clearance (CL), steady -state 
volume of distribution (V ss), and m ean residence time (MRT). Summary statistics of each parameter will be 
reported.
Statistical Considerations, General : This study will provide descriptive safety, efficacy and PK data of 
moroctocog alfa (AF -CC) treatment in previously treated pediatric patients at least 6 months to <16years of 
age. The sample size of each cohort of the study wasbased on the statistical comparison of ABR between 
the first and second segments .  Additional information regarding sample size estimates is provided below .
Statistical Considerations, Prim ary Objective: The primary objective of this study isto dem onstrate a 
mean change in ABR during a period of protocol -defined m oroctocog alfa (AF -CC) prophylaxis 
(~255IU/kg, administered every other day) compared to a period of on -demand therapy with moroctocog 
alfa (AF -CC).  Only subjects who practice on -demand therapy with moroctocog alfa (AF -CC) during 
segment 1, before star ting protocol -defined moroctocog alfa (AF -CC) prophylaxis in segment 2, w ill be 
included in this analysis.  For these subjects, an analysis of variance (ANOVA) will be conducted to 
compare the mean ABR during their on -demand and prophylaxis treatment perio ds.  In a completed ReFacto 
Previously Untreated Patients ( PUP)study (3082A1 -301-WW) , a reduction in the ABR was observed for 
subjects during their periods of prophylaxis ( 2infusions per w eek) compared to their periods of on -demand 
therapy (reduction of 5.7 6.9 bleeds per year [11.85 to 6.15 bleeds per year], ABR decrease of 48%, N=39).  
Based upon this experience, a more conservative decrease in ABR of 40% (corresponding to a mean change 
of 4.75 bleeds per year) and a standard deviation of 7 w ere selec ted for use in sample size calculations.  A 
sample size of 18 OD subjects who practice on -demand therapy in segment 1, follow ed by [CONTACT_232250] 2, provide s80% power to detect such a difference using a 2 -sided alpha level of 0.05.  Due to an 
expe cted attrition rate of up to 25%, approximately 24 OD subjects, who practice on -demand therapy during 
segment 1, were planned to be enrolled to ensure that 18 are evaluable for the comparison of ABRs in the 
on-demand versus the prophylaxis setting.   Becaus e enrollment into the OD cohort has been closed, all 
available data will be analyzed.
Statistical Considerations, Secondary Objectives: A secondary objective is to evaluate the effect of 
dosing schedule on prophylactic efficacy. For the comparison of hig h
-versus low -frequen cyprophylaxis 
dosing schedule, a subset analysis of data from the completed ReFacto PUP study (Wyeth protocol 
3082A1 -301- WW) revealed an ABR of 5.7 5.2 (N=26) in patients receiving a high -frequency prophylaxis 
regimen (3 infusions perweek) com pared to an ABR of 7.1 4.1 (N=13) in patients receiving a 
lower-frequency prophylaxis regimen (2 infusions per w eek).  How ever, the treatment assignment was not 
randomized and prophylaxis regimens were not controlled in that study.  To avoid sel ection bias and 
inter-patient variability affecting outcome, twoprotocol -defined prophylaxis regimens (a high-and a 
low-frequency dosing regimen) w ill be assessed in a crossover design. Assuming an intra -class correlation 
of 30% and a standard deviation of [ADDRESS_280243] deviation of 5 bleeds per year w as used for sample size calculations for the 
comparison between the 2 protocol -defined prophylaxis regimens (A and B).  Given this, 36 RP cohort 
subjects are needed to provide 80% pow er to demonstrate equivalence of the two regimens.  Allow ing for an 
attrition rate of 25%, approximately [ADDRESS_280244] deviation of 
the difference of 6.5 w as obtained requiring 38 subjects to provide 80% pow er to d emonstrate equivalence 

Moroctocog alfa (AF -CC) 
3082B2 -313-WW –(B1831001) 
Final Amendm ent 
10,02 October 2015
Page 19of the two regimens (A and B).  Allow ing for an attrition rate of 30%, approximately 56 RP subjects w ould 
need to be enrolled. The tw o prophylaxis regimens will be considered equivalent if the limits of the 2 -sided 
90% confidence i nterval for the difference in observed mean ABRs fall wholly within the interval defined by 
[CONTACT_143407] 4 bleeds per year.
FVIII:C pharmacokinetics after administration of moroctocog alfa and moroctocog alfa (AF-CC) have been 
well described in a wide rang e of ages.  Younger patients (median age 10 8.3 months, N=59) had low er 
recoveries than older patients (median age 26 12 years, N=101), w ith mean values of 1.5  0.6 and 
2.40.4IU/dL per IU/kg, respectively.  Younger children have also been observed to have higher clearance 
of FVIII:C when adjusted by [CONTACT_232251] -lives.  A secondary objective of this study allows for 
continued characteriz ation of the FVIII:C PK after administration of moroctocog alfa (AF -CC) in children 
younger than 16 years of age, thus improving our understanding the FVIII:C pharmacokinetics in children.  
Descriptive statistics of single -dose PK parameters will define this characterization.  S ubjects opting to 
participate are required to be 6 months to <16 years of age at t he time of the baseline PK assessment.
Interim Report and Analysis: An independent data monitoring committee will provide guidance during the 
course of the study, with review intervals of approximately every 6 months.   Prior to study completion, 
selected (safety, efficacy and/or PK) data from this study may be summarized and reported to regulatory 
authorities to support regulatory submissions or requests. The analyses for these summaries would be based 
on descriptive statistics.
Per discussions with the FDA, a final report for the OD cohort w ill be submitted comparing prophylaxis 
efficacy and safety versus on -demand therapy according to Section 3.3 of the statistical analysis plan.
Additionally, a fter approximately 38evaluable RP subjects, who practiced prophylaxis for both segment 1
and segment 2, complete the study, a final report 
for the RP cohort will be submitted .
Ethical Considerations: This study will be conducted in accordance w ith applicable laws and regulations 
including, but not limited to, the International Conference on Harmonisation Guideline for Good Clinical 
Practice (GCP) and the ethical principles that have their origins in the Declaration of Helsinki.  The 
institutional review board (IRB)/independent ethics committee (IEC) must review and approve the protocol 
and informed consent form (ICF) before any subjects are enrolled.  Before any procedures specified in the 
protocol are performed, the subject’s legally authorized representative must sign and date the 
IRB/IEC -approved informed con sent form.

Moroc tocog alfa (AF -CC) 
3082B2 -313-WW –(B1831001) 
Final Amendm ent 
10,02 October 2015
Page 206.STUDY OVERVIEW
CCThese 56 subjects will crossover to the other moroctocog alfa 
(AF-CC) prophylaxis regimen
     these 28 subjects switch to regimen B 
    these 28 subjects switch to regimen AA 2-Segm ent, Open -Label Study (N = 80Subjects)
Cohort Used 
for 
Comparison 
of 2 
Prophylaxis 
Regim ensRegimen A: 45 IU/kg, twice per week;
Regimen B: 25 IU/kg, every other day
Segm ent 1
(12 m onths)Segm ent 2
(12 m onths)Cohort Used for 
Comparison of 
On-Dem and to 
Prophylaxis
Cohort closed These 24 subjects will switch to protocol -defined 
moroctocog alfa (AF -CC) prophylaxis (24 subjects switch to 
regimen B)Segm ent 1
(6 m onths)
Pharm acokinetic
Characterization
Optional
Subjects from either of the 
subject populations (cohorts) 
defined above and below 
participate in a baseline PK 
assessment
(visit 2)24 subjects who report on -demand therapy 
as current treatment at time of screening
will continue on-demand therapy with 
moroctocog alfa (AF -CC) according to 
investigator prescription
56 subjects will practice 1 of 2 protocol -defined moroc tocog alfa 
(AF-CC) prophylaxis regimens
28 subjects randomized to regimen A 
28 subjects randomized to regimen BCROSSOVERSegm ent 2
(12months)

Moroctocog alfa (AF -CC) 
3082B2 -313-WW –(B1831001) 
Final Amendm ent 
10,02 October 2015
Page 217. STUDY FLOWCHART 1: ROUTINE PROPHYLAXI S (RP) COHORT STUDY PROCEDURES
Study ProceduresaScreeningbSEGME NT 1 (Routine Prophylaxis Treatment Phase)
Study Visit/Contact [CONTACT_5883] 1 2 3 4 5 6 7 8 9 10
Study Intervalc(Day –35
to –1) Day1Mo.1
(1wk)Mo.2
(1wk)Mo.3
(1wk)Mo.4.5
(1wk)Mo.6
(1wk)Mo.7.5
(1wk)Mo.9
(1wk)Mo.10.5
(1wk)
Informed consent/assent X
Demographics, medical 
history, 
hemophilia A informationX
Physical examinationdX
72-hour FVIII washoutX
72-hour FVIII washoutX
72-hour FVIII washoutX
72-hour FVIII washoutX
72-hour FVIII washoutX
CD4 cell count (HIV 
subjects only)X
PT or INR X
Hematology paneleX Xe
Serum chemistryeX
FVIII activity (FVIII:C)fXa,fX X X X X
FVIII inhibitorfXa,fX X X X X
Anti-FVIII antibodyfXfX X X X X
Anti-CHO antibodyfXfX
Anti-TN8.[ADDRESS_280245] diarygX X X X X X
PK assessmenth(optional) Xh
Randomization to regimeniXi
Study drug dispensed X X X X X
Study drug accountability X X X X
Telephone co ntactjX X X X
Concomitant medicationskCOLLECTED at EACH VISIT/CONTACT
[CONTACT_232252]/CONTACT

[CONTACT_232253] (AF -CC) 
3082B2 -313-WW –(B1831001) 
Final Amendm ent 
10,02 October 2015
Page 22STUDY FLOWCHART 1: Routine Prophylaxis (RP) COHORT study procedures (Continued)
Study ProceduresaSEGMENT 2 (Routine Prophylaxis Treatment Phase)Final 
Contact
[CONTACT_61134]/Contact [CONTACT_5883] 11 12 13 14 15 16 17 18 19 20
Study IntervalcMo.12
(1wk)Mo.13.5
(1wk)Mo.15
(1wk)Mo.16.5
(1wk)Mo.18
(1wk)Mo.19.5
(1wk)Mo.21
(1wk)Mo.22.5
(1wk)Mo.24
(1wk)Mo.25
(+10 
days)
Informed consent/assent
Demographics, medical 
history, 
hemophilia A information
Physical examinationd
72-hour FVIII washoutX
72-hour FVIII washoutX
72-hour FVIII washoutX
72-hour FVIII washoutX
72-hour FVIII washoutX
CD4 cell count X
PT or INR 
Hematology panele X X
Serum chemistryeX X
FVIII activity (FVIII:C)fX X X X X
FVIII inhibitorfX X X X X
Anti-FVIII antibodyfX X X X X
Anti-CHO antibodyfX X
Anti-TN8.[ADDRESS_280246] diarygX X X X X
PK assessmenth(optional)
Randomization to regimeni
Study drug dispensed X X X X
Study drug accountability X X X X X
Telephone contact[CONTACT_70557] X X X X
Concomitant medicationskCOLLECTED at EACH VISIT/CONTACT
[CONTACT_232254]/CONTACT
[CONTACT_232255]: Mo = month; wk = week; PT = prothrombin time; INR = international normalized ratio for prothrombin time; FVIII = factor VIII;
CHO = Chinese hamster ovary; TN8.2 = affinity ligand used in study drug purification process; PK = pharmacokinetic.
a. All testing will be performed by [CONTACT_2237].  The lo cal laboratory will also perform FVIII activity and FVIII inhibitor testing to confirm eligibility.
b. Screening period.  Interval starting from the signing of the informed consent/assent and extending up to visit 2 (day 1).  There are up to approximately 35 days in this 
interval (day -35 to day -1).
c. Study day or month.  Visits/contacts 3 (month 1) through 19 (month 24) to be conducted within ± [ADDRESS_280247] (Visit 20, month 
25) to be conducted at least 28 days (+10 days ) from Final Study Visit (Visit 19, month 24).
d. Includes collection of vital signs and weight.  Also includes collection of height at visits 1 (Screening) and 11 (month 12).
e. See Protocol Definitions .  For visit 2 (day 1), hematology panel is only collected for subjects participating in the optional PK assessment .
f. Subjects will observe a minimum 72 -hour FVIII washout before sample collection.  For screening purposes, subjects will be instructed to return to the clinic fol lowing a 

Moroctocog alfa (AF -CC) 
3082B2 -313-WW –(B1831001) 
Final Amendm ent 
10,[ADDRESS_280248] diary dispensed and/or collected.  Subject diary is reviewed at each visit (information about adverse events, concomi tant me dications, study compliance, study drug 
infusions and assessments, less than expected therapeutic effect, and dose escalation and/or changes, if applicable, is revie wed).
h. See Study Flowchart 
2for activities related to this assessment.
i. Randomization will occur only after study eligibility criteria have been confirmed and documented.  Only those subjects who w ill practice prophylaxis during both study 
segments will be randomized to 1 of the 2 protocol -defined prophylaxis regimens to be followed for 12 months during segment 1; these subjects will then crossover to the 
other protocol -defined prophylaxis regimen for 12 months during segment 2.
j. Information about adverse events, concomitant medications, dose escalation and/or changes, if applicable, and study compliance will be collected during these contacts.  
Can be conducted at appropriately scheduled clinic visits if preferred.
k. Collected at each visit/contact [CONTACT_232256]/assent form is signed to the final stud y contact.
8.STUDY FLOWCHART 2: PHARMACOKINETIC AS SESSMENT VISIT 2 (DAY 1)
Study ProceduresaPredose: -2-0 hr Dose: 0 hr 0.5 hr (± 3 min) 8 hr (± 48 min) 24 hr (± 1 hr) 28 hrb(± 1 hr) 32 hr (± 1 hr)
Physical exam and We ight X
Vital signs X X
Blood sample collections for:
FVIII activity
72-hour FVIII washoutX X X X X X
FVIII inhibitor X
Anti-FVIII antibody X
Anti-CHO antibody X
Anti-TN8.2 antibody X
Hematology pa nelcX
Study drug administration
(50 5 IU/kg , rounded to nearest 
complete vial )X
Concomitant medications COLLECTED for the COURSE of the ASSESSMENT
Adverse events COLLECTED for the COURSE of the ASSESSMENT
Abbreviations: FVIII=facto r VIII; hr=hour; min=minute; CHO=Chinese hamster ovary; TN8.2=affinity ligand used in study drug purification process.
a.Optional pharmacokinetic assessment is conducted at visit 2 (day 1).  Subjects must be in a nonbleeding state for this assessment.  All t esting will be 
performed by [CONTACT_2237].
b.The 28 -hour sample collection is optional.
c.See Protocol Definitions .

Moroctocog alfa (AF -CC) 
3082B2 -313-WW –(B1831001) 
Final Amendm ent 
10,[ADDRESS_280249] o and Moroctocog alfa (AF- CC)
Hemophilia A is an X -linked recessive disease in which clotting factor VIII (FVIII) is 
deficient or inactive.  Patients with a low level of FVIII have an increased tendency  to bleed.  
When the levels of FVIII are very  low ( ≤2% of normal), spontaneous bleeding epi[INVESTIGATOR_232208].  Infusing patients with a concentrated formulation of the missing FVIII protein can 
control the bleeding.  Until the late 1980s, such concen trates were produced exclusively  from 
human (or porcine) plasma.  However, a combination of the risk of transmission of viral 
diseases, especiall y the human immunodeficiency virus (HIV), and rapi[INVESTIGATOR_2478] y evolving 
recombinant technolog y drove the development of recombinant DNA -derived coagulation 
products.  Recombinant DNA technolog y also provides the potential to produce virtuall y 
unlimited quantities of virally  safe products.
The first recombinant FVIII products (rFVIII) were referred to as “full -length” in tha t they  
were derived from plasmid DNA expression constructs containing the entire coding sequence 
of the FVIII protein.  Later, it was observed that removal of the central B domain of FVIII 
increased the manufacturing y ield without compromising the biologic al activity  of the 
molecule.1,2  To enhance the production of rFVIII,  a B-domain deleted (BDD) rFVIII was 
developed.  This culminated in the licensure of ReFacto®.  The active substance of ReFacto 
is a recombinant B -domain deleted, murine monoclonal -antibody  purified, solvent -
detergent 
treated, and albumin -free formulated FVIII, (BDDrFVIII).  The amino acid sequence is 
comparable to the 90 + 80 kDa form of FVIII and po sttranslational modifications are similar 
to those of the plasma -derived molecule.3, 4  ReFacto has functional characteristics 
comparable to those of endogenous Facto r VIII.3, 4, 5
9.2.
Manufacturing Changes for Moroctocog alfa (AF- CC)
ReFacto 
was manufactured using 2 raw materials that carr y with them a minor but finite risk 
of introducing viral contaminants into the process stream.  Human serum albumin (HSA) was 
used in the cell culture medium, and the purification process use da murine monoclonal 
antibody  that was manufactured b y a process employ ing bovine and human -derived 
components.  To address these potential risks, Wyeth developed an alternative manufacturing 
process for ReFacto which included (1) the use of a reformulated, HSA -free cell culture 
medium for growth and production, (2) th e use of a chemically  synthesized poly peptide 
affinity  ligand (TN8.2) in a column chromatography  purification step in lieu of t he murine 
monoclonal -antibody  purification step, and (3) the addition of a virus -retaining membrane to 
the final manufacturing st eps.  These manufacturing changes expanded upon the 
comprehensive multifaceted viral safet y program alread y in place for ReFacto.6, [ADDRESS_280250] has been designated moroctocog alfa 
(AF-CC).

Moroctocog alfa (AF -CC) 
3082B2 -313-WW –(B1831001) 
Final Amendm ent 
10,02 October 2015
Page 25Later, additional changes were also incorporated into the manufacturing process for 
moroctocog alf a (AF -CC), coincident with a manufacturing site transfer, to allow use of the 
common one- stage (OS) assay  for monitoring moroctocog alfa (AF- CC) replacement 
therap y.
The BDDrFVIII DNA construct and the final formulation are identical for ReFacto and 
moroct ocog alfa (AF -CC).  Biochemical characterizations indicate that the active substance, 
BDDrFVIII, produced b y both manufacturing processes (ReFacto and moroctocog alfa 
[AF-CC]) is comparable with respect to structure and function.
ReFacto/moroctocog alfa (AF-CC) has been licensed for use since 1999 in the European 
Union (EU) and since 2000 in the [LOCATION_002] (US).  I n the EU moroctocog alfa (AF -CC) is 
marketed under the trade name [CONTACT_232312].  In the US, moroctocog alfa (AF -CC) is 
distributed under the tra de name [CONTACT_232313].  Globally , as of August 2014, moroctocog alfa 
(AF-CC) was approved in 48countries and marketed in 19countries.8
9.3.
Clinical Experience With Moroctocog alfa (AF- CC)
Extensive clinical trial experience had alread y been compi[INVESTIGATOR_232209] (AF- CC) 
before the last manufacturing changes (ie, before the modifications facilitating use of the OS 
assay  and the change of manufacturing site): a pharmacokinetic crossover study  showed 
bioequivalence t o ReFacto (study  3082B1 -305- GL); and 2 open -label, single -arm studies 
were initiated to assess safet y and efficacy in previously  treated patients (PTPs) at least 
6years of age (studies 3082B1 -
306-GL [study  306] and 3082B1 -307- GL [study  307]).  
Results from study  306 showed moroctocog alfa (AF -CC) to be safe and efficacious for 
hemophilia A treatment in 110 PTPs (median moroctocog alfa (AF -CC) exposure day s [EDs] 
= 58), and stud y 307 demonstrated the long -term safet y of moroctocog alfa (AF -CC) in 98 of 
these PTPs who elected to participate in this extension study  after completing study  
306(median moroctocog alfa [AF -CC] EDs = 169 over median duration of 521 day s).
The safet y and efficacy  of moroctocog alfa (AF -CC) manufactured with the most recent 
manufacturing changes (ie, modifications allowing use of the OS assay  and new 
manufacturing site), has been evaluated in [ADDRESS_280251] 12 y ears of age, 
completed study 3082B2 -310- WW (study  310) and completed study  3082B2 - 311-WW 
(study  311).
Study 310 was an open
-label safety  and efficacy  evaluation of moroctocog alfa (AF -CC) for 
the control and prevention of bleeding in PTPs with severe or moderatel y severe hemophilia 
A during moroctocog alfa (AF -CC) prophy laxis treatment.  In this open -label st udy, patients 
used moroctocog alfa (AF -CC) according to an assigned routine proph ylaxis regimen, 
accruing a minimum of [ADDRESS_280252] 
demonstrated the bioequivalence of ReFacto and the full- length plasma -derived FVIII 
(pdFVIII) using the chromogenic substrate assay ,9a double -blind, crossover evaluation in the 
310 study  used the OS assay to demonstrate the bioequivalence of moroctocog alfa (AF -CC) 
and a full -length recombinant FVIII product (Advate®).

Moroctocog alfa (AF -CC) 
3082B2 -313-WW –(B1831001) 
Final Amendm ent 
10,02 October 2015
Page 26Study  311 was also an open -label stud y with the primary efficacy objective of characterizing 
the ability  of moroctocog alfa (AF -CC) to support patients during and after surgery .  The 
safet y and efficacy of moroctocog alfa (AF -CC) was assessed in patients with severe or 
moderatel y severe hemophilia A undergoing major elective surgery.  Factor VIII infusions 
were administered as bolus injection s or as a continuous infusion, over a period of at least 
6days following the surgical procedure.
Collectively , results from studies 310 and 311 support the use of moroctocog alfa (AF -CC) 
for the control and prevention of bleeding epi[INVESTIGATOR_1841], and for surgica l prophy laxis in PTPs 
with hemophilia A.
9.4.Rationale for the Current Moroctocog alfa (AF -CC) Study (3082B2- 313-WW)
While studies 310 and 311 are designed to evaluate the safety  and efficacy  of moroctocog 
alfa (AF -CC) in PTPs who are 12 y ears of age or older, the current study  will provide these 
data for moroctocog alfa (AF- CC) treatment in pediatric PTPs who are younger than [ADDRESS_280253] 
patients.
Prophy laxis therapy  (ie, the regularly  scheduled administration of a factor replacement 
product for the prevention of bleeding) is widel y advocated as the optimal treatment modality 
for patient s affected with the more severe forms of hemophilia A.  Several studies have 
concluded that it is preferable to on- demand therapy , as prophy laxis affords lower bleeding 
rates, better retention of joint integrity , and qualit y of life improvements (eg, fewer
hospi[INVESTIGATOR_232210]).10, 11, 12, 13, 14  In view of the established 
benefits of proph ylaxis in pediatric patients with hemophilia, the National Hemophilia 
Foundation (NHF)
,15the World Federation of Hemophilia ( WFH) ,16and the World Health 
Organization (WHO) now endorse prophy laxis .  Despi[INVESTIGATOR_232211]
-demand therap y, more specific questions still exist.  For 
example, direct clinical information on optimal prophy laxis dosing strategies is limited.  
Recently , the Cochrane collaboration recommended conducting additional prospective, 
randomized controlled trials to determine optimal prophylactic regimens and to assess the 
effectiveness of clotting factors.[ADDRESS_280254] achieved when the therapy  is initiated at an earl y age, perceived dosing 
frequency  requirements are often a maj or obstacle for its practice in pediatric populations.  
Thus, corollary  data, establishing associations between dosing frequency  and effective 
prophy laxis, would be especiall y meaningful for younger patients. 
To achieve itsobjectives, this study  evaluate s moroctocog alfa (AF
-CC) in the context of two
settings.  A cohort of subjects was enrolled who practice d on-demand therapy  for a 6- month 
period during segment 1, then switch
ed to proph ylaxis with moroctocog alfa (AF -CC) for a 
12-month period in s egment 2, practicing a protocol -defined regimen (25 5IU/kg, 
administered every  other day ).This regimen has been well characterized and has 
demonstrated e fficacy  relative to on -demand therapy , although in a different patient 
population.12  Asecond cohort, comprising all other subjects , will practice a single 
moroctocog alfa (AF -CC) treatment modality , prophy laxis, during this study , but treatment 

Moroctocog alfa (AF -CC) 
3082B2 -313-WW –(B1831001) 
Final Amendm ent 
10,02 October 2015
Page 27will include practice of each of the twoprotocol -defined regimens; the se subjects will follow 
oneof the two randomly  assigned protocol- defined regimens for a 12 -month period
(segment 1), and then will crossover to the other regimen for a second 12- month treatment 
period (segment 2) .  Study  subjects will be hereafter referre d to by  [CONTACT_232257] 1 treatment 
modality : on-demand (OD) subjects and routine prophy laxis (RP) subjects.  This study  
design allows direct evaluation of moroctocog alfa (AF -CC) in the prophy laxis and 
on-demand settings, as well as a direct comparison betw een 2 different moroctocog alfa 
(AF-CC) prophy laxis -dosing schedules.  The duration of moroctocog alfa (AF -CC) treatment 
in this study  (18 -
24 months depending on the cohort) ensures that sufficient experience with 
moroctocog alfa (AF -CC) is obtained.
Pharmacokinetic assessment of FVIII:C after FVIII therap y has shown lower FVIII :C
recovery , in y oung children . For moroctocog alfa, this has also been observed : a mean
incremental recovery  of 1.50.6IU/dL per IU/kg, in 59children with median age 10 8.3 
months was reported compared with mean incremental recovery  of 2.40.4 IU/dL  perIU/kg
in101patients with a median age of 26[ADDRESS_280255] higher 
clearance, when adjusted for bod y size and shorter half -lives compared with older children 
and adults.  Asecondary  objective of this study  is to continue to characterize the 
pharmacokinetics of moroctocog alfa (AF -CC) in pediatric patients.  To achieve this 
objective, a subset of enrolled subjects will pa rticipate in a pharmacokinetic assessment 
conducted at the start of the study .
Another secondary  objective of this study  is to define the safet y and efficacy of moroctocog 
alfa (AF -CC) in pediatric patients, including the characterization of the incidence of “less 
than expected therapeutic effect”.
Enrollment into the on- demand (OD) cohort has been closed.  To date, there aredata 
indicating that prophy laxis therapy  controls bleeding epi[INVESTIGATOR_232212]- demand 
therap y.  Subsequent to the initiation of t his protocol , Xyntha has been approved for 
on-demand use in children . The availability  of the completed pharmacokinetic assessment in 
the submission means enrollment into the pharmacokinetic (PK) assessment is optional .
Given that proph ylaxis 
has replace d OD therap y asthe preferred standard of medical care , 
the study  will continue enrollment into the RP cohort to assess the effect of a high (25IU/kg 
every  other day )versus low (45IU/kg twice per week) frequency  dosing schedule on the 
efficacy  of moroct ocog alfa (AF -CC) prophy laxis for male subjects 6months to <16years 
of age . 
Refer to the most recent version of the investigator’s brochure for a summary  of findings 
from nonclinical studies that potentially  have clinical significance and from clinical studies 
that are relevant to the study .  Also refer to the most recent version of the investigator’s 
brochure for a summary  of the known and potential risks and benefits, if any , to human 
subjects.

Moroctocog alfa (AF -CC) 
3082B2 -313-WW –(B1831001) 
Final Amendm ent 
10,02 October 2015
Page 2810.OBJECTIVES
10.1. Primary Objective
To demonstrate that moroctoc og alfa (AF -CC) prophy laxis reduces annualized bleeding rates 
relative to on -demand therap y.  Enrollment into the on- demand (OD) cohort has been closed .
10.2. Secondary Objectives
To assess the effect of a high (25IU/kg every  other day )-versus low (45IU/kg 
twice per week) -frequency  dosing schedule on the efficacy  of moroctocog alfa 
(AF-CC) prophy laxis.
To continue to characterize the PK of FVIII:C after administration of moroctocog 
alfa (AF -CC) in children 6months to <16 years of age.   Enrollment into the PK
assessment is optional .
To describe moroctocog alfa (AF -CC) efficacy  and safety in children, including 
characterization of the incidence of “less than expected therapeutic effect” (see 
Section 18.2).
11.STUDY DESIGN
11.1. Description
There will have been two cohorts enrolled into the study ; one in which the subject practices 
on-demand therap y for the first segment of the study, followed b y routine prophylaxis for the 
second segment, and, another cohort in which the subject practices routine prophy laxis for 
both segments.  Study  subjects will be hereafter referred to by  [CONTACT_232257] 1 treatment 
modality : on-demand (OD) subjects and routine prophy laxis (RP) subjects.  Enrollment into 
the OD cohort has be en closed. Enrollment for the RP cohort is ongoing.
Enrollment for the RP cohort will continue and will be conducted as an open -label, 
multicenter trial of moroctocog alfa (AF -CC) in approximately  56subjects (6months to 
<
16years of age) with moderatel y severe to severe hemophilia A.  The study will be 
conducted in 
two 12- month segments (Also refer to Section 6).
At study  start, a subset of subjects may participate in optional 
assessments t o characterize the 
PK of FVIII after moroctocog alfa (AF- CC) administration.  Subjects who are eligible and 
optto participate will undergo a baseline PK assessment, receiving a single open -label dose 
of moroctocog alfa (AF -CC) ( 50 5IU/kgrounded to the nearest complete vial ) with blood 
sampled for FVIII activity
 measurements before and at 0.5, 8, 24, 28 (optional), and 32 hours 
after the start of the infusion. 
All RP subjects will practice proph ylaxis with moroctocog alfa (AF -CC) according to 1 of 
2randomly  assigned moroctocog alfa (AF -CC) regimens, each delivering approximately  
90IU/kg/week, but differing in dosing schedule.  Randomization will be stratified b y 
hemophilia A severit y: FVIII activity  <1% or 1 -2% (central laboratory  screening result).  
Each segment will be 12 months in duration.

Moroctocog alfa (AF -CC) 
3082B2 -313-WW –(B1831001) 
Final Amendm ent 
10,[ADDRESS_280256] segment , subjects will be randoml y assigned to Regimen A: 45 5IU/kg, 
administered twice perweek or Regimen B: 25 5 IU/kg, administered every  other day .
For regimen A, the interval between proph ylactic infusions should be 3 to 4 day s, and should 
not exceed 4 days.  For regimen B, the interval between proph ylactic infusions should be 
approximatel y 48 hours (eg, an appropriate dosing schedule for Regimen B is as follows 
Monday , Wednesday , Friday , Sunday , Tuesday , Thursday , Saturday , Monday …etc). 
After completion of the first segment , all subjects will cross over to the alternate proph ylactic 
regimen for segment 2.  Subjects who received Regimen A in segment [ADDRESS_280257]’s treatment will be escalated to a higher intensity  prophy laxis 
regimen comprised of the most intensive components of both regimen s A and B 
(455 IU/kg, administered every  other day ) if criteria justify ing regimen escalation are met 
(see Section 15.3.3).  Subjects who meet dose escalation criteria while on this more int ensive 
regimen may  dose escalate to a higher intensity  regimen designated by  [CONTACT_093].  The 
subject will follow the assigned regimen(s) until the respective 12-month period of 
prophy laxis with study  drug has been completed (segment 1 or 2); the
12-month period is 
inclusive of treatment time on all the prophy laxis regimens assigned during the respective 
study  segment.  During prophy laxis, subjects will also use moroctocog alfa (AF -
CC), as 
needed, for the treatment of bleeds (ie, on -demand), should they  occur.
Clinical and laboratory  examinations, including assessments for FVIII inhibitor development, 
will be conducted during the course of the study .
11.2. Approximate Duration of Subject Participation
Subjects enrolled in the OD subject cohort participated i n the study  for approximately  
20 or 26 months, while subjects enrolled in the RP cohort will participate in the study  for 
approximatel y 26 months.  This includes approximately 35 days for screening, a 6 -month or 
12-month treatment period during segment 1, a 12- month treatment period during segment 2, 
and approximatel y 1 month (at least 28 day s) for a final safety  follow -up assessment (Final 
Study  Contact).  Completion of the Final Study  Contact [CONTACT_232258]’s participation 
in the study .
11.3. Approximate Duration of Study
The duration of this study  will be approximatel y 98months ( including 26months after the 
last RP subject is enrolled) .  The end of the study  is the Final Study  Contact [CONTACT_232259] (Final Study  Contact [CONTACT_232260] 28 day s after the Final Study  Visit).  A final 
safet y follow- up assessment is performed during the Final Study  Contact; this follow -up 
assessment includes the reporting of an y adverse events that may have occurred during the 
time between the Final Study  Visit and the Final Study  Contact [CONTACT_232261].

Moroctocog alfa (AF -CC) 
3082B2 -313-WW –(B1831001) 
Final Amendm ent 
10,[ADDRESS_280258] s(and legal acceptable representative , if req uired) must participate in the informed 
consent/assent process and sign and date the informed consent/assent form before an y stud y 
procedures or screening activities specified in this protocol are performed ( the informed 
consent/assent form for signature m ust have been approved by [CONTACT_232262] ( IRB)/independent ethics committee ( IEC)andthe Sponsor ).  Prospective subjects may  
be notified of the stud y’s existence, but no stud y procedures may  be performed before 
obtaining informed cons ent/assent.  The investigator will maintain a subject- screening 
logbook at the study  site.  All subjects screened at the study  site will be entered into the 
logbook ( see Section 23).
After obt aining informed consent/assent, the investigator and monitor determine a subject’s 
eligibility  by [CONTACT_232263].  The central laboratory will be used for 
all screening blood tests.  The local laboratory  will also be used specifical ly for 2 tests: 
FVIII activity  (FVIII:C) and FVIII inhibitor.  Local laboratory  measurements of FVIII:C and 
FVIII inhibitor will be used by  [CONTACT_232264] , although parallel samples 
will be anal yzed at the central laboratory  and wi ll also be used to confirm eligibility  for 
subjects.  ( NOTE :During the treatment phase of the study, all tests for FVIII:C and/or FVIII 
inhibitor performed at the local laboratory should have duplicate samples from the same 
phlebotomy shipped to the centr al laboratory for analyses.  The treatment phase starts at 
visit 2 and ends at the Final Study Visit.)  I f the local or central laboratory  results for either 
FVIII:C or FVIII inhibitor show the subject is ineligible, the subject will be considered a 
screen failure.  The Sponsor’s clinician may  be consulted regarding eligibility  of particular 
subjects if circumstances warrant further discussion.
12.1. Inclusion Criteria
For all subjects participating in the study:
1.Male subjects with moderatel y severe to severe hem ophilia A (FVIII:C  2%) b y both
the local laboratory  and the central laboratory  at screening.
2.A negative FVIII inhibitor by  [CONTACT_232265] (for local laboratory , a Bethesda inhibitor titer less than the up
per limit of 
normal [UL N] for the laboratory  performing the assay  and is not reported to be 
≥0.6 Bethesda Units [BU]/mL ; for central laboratory , Bethesda inhibitor titer 
<0.6 BU/mL  by [CONTACT_232266] ).
3.A medical history  negative for a past FVIII inhibitor (see Protocol Definitions).

Moroctocog alfa (AF -CC) 
3082B2 -313-WW –(B1831001) 
Final Amendm ent 
10,02 October 2015
Page 314.Age 6 months to <16 y earsat the time of screening visit (study  visit 1).
5.Previous experience of FVIII therap y ([ADDRESS_280259] [see Protocol Definitions]).
6.Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) 5.0 × ULN, 
and bilirubin  2 mg/dL  (<35 mol/L).
7.Serum albumin  the lower limit of normal (LL N).
8.Serum creatinine 1.25 × ULN.
9. Platelet count 100,000/L.
10.Absolute CD4 count >400/ L for subjects with HIV only .
11.Prothrombin time (PT) 1.25 × ULN, or international normalized ratio (INR) 1.5.
12.The subject is not receiving treatment for HIV or hepatiti s infection, or the subject is 
on a stable antiviral regimen at the time of signing the consent/assent form (ie, stable 
dosing for at least 3 months before signing the consent/assent form).
13.The subject is able to comply  with the mandatory 72 -hour FVIII was hout preceding 
each FVIII:C and FVIII inhibitor assessment during the study .
14. Male subjects able to father children must agree to use a highly  effective method of 
contraception throughout the study  and for at least [ADDRESS_280260] dose of 
assigned tr eatment. 
15.Evidence of a personally  signed and dated informed consent /assent document 
indicating that the subject (or a legall y acceptable representative/parent(s)/legal 
guardian) has been informed of all pertinent aspects of the study .
16.Subjects who are wil ling and able to compl y with scheduled visits, treatment plan, 
laboratory  tests, and other study  procedures.
The Sponsor’s clinician should be consulted about prospective subjects with complex 
medical or laboratory  histories relevant to inclusion criteria .
Additional criteria for subjects participating in the PK assessment:
1.Male subjects as described immediately  above except they  must have a FVIII:C of 
1% confirmed b y the central laboratory screening test .
2.Age 6 months to <16 years at time of PK assessment (study  visit 2).
3. The subject’s size is sufficient to permit PK- related phlebotomy .

Moroctocog alfa (AF -CC) 
3082B2 -313-WW –(B1831001) 
Final Amendm ent 
10,[ADDRESS_280261] is able to comply  with the procedures conducted during the PK 
assessment, including a mandatory  72-hour washout period preceding the PK 
assessment. 
12.2.
Exclusion Criteria
1.A history  of FVIII inhibitor (clinical or laboratory -based assessment).  For laboratory  
assessments, an y measured Bethesda inhibitor titer 0.6 BU/mL , regardless of the 
laboratory  normal range, or any  measured Bethesda inhibitor titer greater than the 
ULN for the laboratory  performing the assay .
2.Presence of a bleeding disorder in addition to hemophilia A.
3.Treatment with an y investigational drug or device within 30 days before the time of 
signing the consent/assent for m.
4.Major or orthopedic surgery  planned to occur within the period following the signing 
of the consent/assent form to the Final Study  Contact (ie, during the course of the 
study ).
5.Regular (eg, daily , every  other day ) use of antifibrinoly tic agents or medic ations 
known to influence platelet function such as aspi[INVESTIGATOR_232213]-inflammatory  drugs (NSAIDs).
6.Regular, concomitant therap y with immunomodulating drugs (eg, intravenous 
immunoglobulin [IVIG], routine sy stemic corticosteroids).
7.Known hypersensitivity  to hamster protein.
8.Any condition(s) that compromises the subject’s ability  to comply  with and/or 
perform stud y-related activities or that poses a clinical contraindication to study  
participation (these conditions include, but are not limi ted to, inadequate medical 
history  to assure study  eligibility ; inability  to properly  store study  drug; expectation 
of poor compliance in study  related documentation).
9.Unwilling or unable to follow the terms of the protocol.
10. Subjects who are investigationa l site staff members directl y involved in the conduct 
of the study  and their family  members, site staff members otherwise supervised by  [CONTACT_1275], or subjects who are [COMPANY_007] emplo yees directly  involved in the conduct of 
the study .
11.Male subjects able to father children who are unwilling or unable to use a highly  
effective method of contraception as outlined in this protocol for the duration of the 
study  and for at least [ADDRESS_280262] or longer 
based upon the compound’s half -life characteristics.

Moroctocog alfa (AF -CC) 
3082B2 -313-WW –(B1831001) 
Final Amendm ent 
10,02 October 2015
Page 33The Sponsor’s clinician should be consulted about prospective subjects with complex clinical 
or laboratory  histories relevant to Exclusion Criteria .
12.3. Life Style Guidelines 
All male subjects who are able to father children and are sexually  active and at risk for 
pregnancy  must agree to use a highly  effective method of contraception consistently  and 
correctly  for the duration of the active treatment period and for at least [ADDRESS_280263]/will confirm that the subject has selected an appropriate method of 
contraception for the individual subject and his partner from the per mitted list of 
contraception methods (see below) and instruct the subject in its consistent and correct use.  
Subjects need to affirm that they  meet the criteria for correct use of at least 1 of the selected 
methods of contraception.  The investigator or h is/her designee will discuss with the subject 
the need to use highl y effective contraception consistently  and correctly  according to the 
schedule of activities and document such conversation in the subject’s chart.  I n addition, the 
investigator or his or her designee will instruct the subject to call immediately  if the selected 
contraception method is discontinued or if pregnancy  is known or suspected in the subject or 
the subject’s partner. 
Highly  effective methods of contraception are those that, alone or in combination, result in a 
failure rate of less than 1% per year when used consistently  and correctly  (ie, perfect use) and 
include the following:
1.
Established use of oral, inserted, injected, implanted or transdermal hormonal 
methods of contraception i s allowed provided the subject plans to remain on the 
same treatment throughout the entire study  and has been using that hormonal 
contraceptive for an adequate period of time to ensure effectiveness.
2.Correctl y placed copper - containing intrauterine device (IUD). 
3.Male condom or female condom used WI TH a spermicide (ie, foam, gel, film, 
cream, or suppository ).  For countries where spermicide is not available or condom 
plus spermicide is not accepted as highl y effective contraception, this option is not 
appro priate.
All sexually  active male subjects must agree to prevent potential transfer of and exposure to 
drug through semen to their partners b y using a condom consistently and correctl y, beginning 
with the first dose of investigational product and continuing for at least [ADDRESS_280264] 
dose.
12.4. Sponsor’s Qualified Medical Personnel
The contact [CONTACT_1133]'s appropriately qualified medical personnel for the 
study  is documented in the study  contact [CONTACT_232267] .
To facilitate access to appropriatel y qualified medical personnel on stud y-related medical 
questions or problems, subjects are provided with a contact [CONTACT_1137]. The contact [CONTACT_4662], 

Moroctocog alfa (AF -CC) 
3082B2 -313-WW –(B1831001) 
Final Amendm ent 
10,[ADDRESS_280265]’s participation in the study .The contact [CONTACT_167170]; however, it should be used 
only in the event t hat the established communication pathway s between the investigational 
site and the study  team are not available. It is therefore intended to augment, but not replace, 
the established communication pathway s between the investigational site and the study  team 
for advice on medical questions or problems that may  arise during the study .The contact 
[CONTACT_8865] b y the subject directly , and if a subject calls that number, he 
or she will be directed back to the investigational site.
13.PRIOR TRE ATMENT
All treatment received within 30 days before signing the consent/assent form will be 
recorded.
14. CONCOMITANT TREATMENT
14.1. Prohibited
Concomitant treatment with FVIII concentrates, other than moroctocog alfa (AF -CC) study  
drug, is not allowed during the treatment phase of this study : the treatment phase starts at 
visit 2 (day 1) and ends at the Final Study  Visit (ie, visit 19, month 24 for RP subjects).  
After completion of the treatment phase of this study , subjects may  use the FVIII concentrate 
of their choice and should not use study  drug.
Subjects should not receive drugs with antiplatelet effects (eg, aspi[INVESTIGATOR_248]) or use certain NSAIDs 
to a degree that, in the opi[INVESTIGATOR_94367]’s clinician, affects the 
hemostatic function of the subjec t, and/or affects the subject’s FVIII therapy .
The regular use of immunomodulating drugs (eg, IVIG, routine s ystemic corticosteroids) is 
prohibited.
14.2. Permitted
The subject’s regular medication, other than FVIII concentrates, may  continue unchanged, 
and will be recorded.  Analgesics, as well as other therap y considered necessary  for the 
subject’s well -being during the study , may  be given at the discretion of the investigator.  
Subjects must use only  study  drug (moroctocog alfa [AF -CC]) for FVIII therap y durin g the 
treatment phase of this study : the treatment phase starts at visit 2 (day  1) and ends at the Final 
Study  Visit 19, month 24 for RP subjects).
Subjects with HI V and/or hepatitis virus infection(s) will be permitted to continue with any  
stable, noninve stigational treatment throughout the study .  Licensed antiviral medications, 
including but not limited toprotease inhibitors, interferon, and ribavirin, are permitted 
provided subjects are on stable dosing for at least 3 months before the signing of the 

Moroctocog alfa (AF -CC) 
3082B2 -313-WW –(B1831001) 
Final Amendm ent 
10,02 October 2015
Page 35consent/assent form.  Subjects must remain on a stable regimen of antivirals over the course 
of this study .  The Sponsor’s clinician should be consulted about prospective subjects with 
circumstances that may  conflict with these criteria regarding antiviral medications.
Major surgery  or orthopedic surgery  planned to occur within the period following the signing 
of the consent/assent form to the Final Study  Contact (ie, during the course of this study ) is 
an exclusion criterion for this study .  Required minor surgery , or major/orthopedic surgical 
procedures which were unplanned at the time of signing the consent/assent form, will be 
allowed during the course of this study , pending approval from the Sponsor’s clinician.  
Moroctocog alfa (AF -CC) study  drug will b e the only  FVIII replacement product used to 
achieve and maintain normal hemostasis through a surgical procedure.  See Section 15.3.4
for further details.
15. PROCEDURES 
The following description provides information on the procedures and activities of 
subjects/caregivers and investigators (or designees) as the study  proceeds.  
[NOTE :Enrollment has been closed in the OD cohort.   Details of the OD cohort can be 
found in Amendment 9 of this protoco l.  The RP cohort enrollment remains active and PK 
assessment portion continues as optional
.]  Due to the young age of some subjects in this 
study , man y activities will be performed b y a subject’s caregiver (eg, reporting of bleeds and 
study  drug usage); w
here applicable in this protocol, the term subject will also refer to 
caregiver.  Please also refer to Sections 7 and 8foran overview of stud y procedures.
15.1. Study Procedures for RP Cohort
Please also refer to the study  flowchart in Section 
7, for an overview of study  procedures.
15.1.1.
Consent/Assent
All subjects must review and sign a consent form that has be en approved b y both the 
appropriate IRB/IEC andthe Sponsor (the consent form must be approved by [CONTACT_232268]/IEC before it can be used for the trial at that site ).  Where deemed 
appropriate b y the IRB/IEC, the subject should also sign a n assent form ( the assent form must 
be approved by [CONTACT_232269]/IEC before it can be used for the trial at that 
site).  Subjects who are under the legal age of consent, must have a legall y acceptable 
representative review, approve and sig n consent for the study (also see Section 29.3).  The
consent process must explain to the subject (and legal acceptable representative) that they  
may withdraw their consent/assent at an y time for any  reason.  A note (dated and timed) must 
be made in the patient’s medical record that the subject is participating in this study
 and that 
consent/assent was obtained.  Collection of adverse events (AEs), as well as bleeds and 
medications, begins afte r the signing of the consent/assent form and completion of the 
medical history.  Signing the consent/assent form marks the start of study participation.
15.1.2. Payment of Subjects
Subjects may  be reimbursed for expenses related to study  activities.  Any  payments must 
meet applicable law and regulations and be approved by  [CONTACT_30246]/IECs.

Moroctocog alfa (AF -CC) 
3082B2 -313-WW –(B1831001) 
Final Amendm ent 
10,02 October 2015
Page 3615.1.3. Study Visit 1 (Screening Visit) - RP Cohort
Following consent/assent, subjects will undergo the following screening activities to 
determine if they  are eligible for the study .  Results from the central laboratory , designated 
by [CONTACT_1034] , will be used to determine eligibility  as noted.  Local laboratory  test results 
will also be used to determine eligibility  as noted.  Screening procedures will collect the 
following:
Obtai n informed consent/assent.
Demographic information, medical history  (including HIV status and history  of 
hepatitis infections), medication history  (including hepatitis vaccinations), and 
hemophilia A history .
Current hemophilia A treatment information (eg, prophy laxis or on- demand therap y).
Complete phy sical examination including vital signs (temperature [Celsius], blood 
pressure, pulse, and respi[INVESTIGATOR_1516]), bod y weight (kilograms), and height (centimeters) .
Blood sample for:
CD4 cell count (central laboratory ) for subjects with HI V onl y.
PT or INR (central laboratory ).
Hematology  panel (see Protocol Definitions; central laboratory ) .
Serum chemistry  (see Protocol Definitions; central laboratory ) .
FVIII:C (after a 72- hour FVIII washout; local and central laboratories; results 
from both local and central laboratories must meet inclusion criteria ).
FVIII inhibitor (after a 72-hour FVIII washout; local and central laboratories; 
results from both local and central laboratories must meet inclusion criteria ).
anti-FVIII antibody (see Protocol Definitions; collected after a 72 -hour FVIII 
washout; frozen and sent to central laboratory  for enzy me-linked immunosorbent 
assay  [ELISA] anal ysis).
anti-CHO antibody
 (see Protocol Definitions; collected after a 72 -hour FVIII 
washout; frozen and sent to central laboratory  for ELISA anal ysis).
anti-TN8.2 antibod y (see Protocol Definitions; collected after a 72 -hour FVIII 
washout; frozen and sent to central laboratory  for ELISA anal ysis).
All screening procedures that do not require a [ADDRESS_280266] experiences a bleed 

Moroctocog alfa (AF -CC) 
3082B2 -313-WW –(B1831001) 
Final Amendm ent 
10,[ADDRESS_280267] 
a repeat 72 -hour FVIII washout before relevant screening sample collections.
FVIII:C and FVIII inhibitor testing will be performed at both the local and the central 
laboratories .  Subjects must have FVIII:C 2% b y both the local laboratory and the central 
laboratory .  Subjects must have negative FVIII inhibitor tests by  [CONTACT_232270]  (for local laboratory , a Bethesda inhibitor titer < ULN for the 
laboratory performing the assay  and is not reported to be 0.6 Bethesda Units [BU]/mL ; for 
central laboratory , Bethesda inhibitor titer <0.6 BU/mL  by [CONTACT_232266] ).  Once results 
are received, subjects who are deemed eligible will return for visit 2 (day  1) within 
approximatel y 35 days after the screening visit.
Subjects who do not meet study  eligibility  criteria will be considered screen failures (please 
refer to the Study  Reference Manual for data rec ording instructions for screen failures).  In 
the event that contradictory  FVIII:C or FVIII inhibitor results are reported by  [CONTACT_232271], a subject is ineligible for the study  if either the local or central 
laboratory  results do not meet study  eligibility  criteria (eg, if a subject is ineligible for the 
study  based on the central laboratory  results for FVIII:C or FVIII inhibitor, the subject will 
be considered a screen failure even if the local laboratory  results indicate the subject is 
eligible; similarly , if a subject is ineligible for the study  based on the local laboratory  results 
for FVIII:C or FVIII inhibitor, the subject will be considered a screen failure even if the 
central laboratory  results indicate the subject is eligible) .
Please refer to the Stud y Reference Manual for further details on the collection and shippi[INVESTIGATOR_232214].
Subjects will receive the appropriate materials (ie, Subject Diary ) and instructions to record 
any AEs, bleeds, and concomitant medication use.
15.1.4. Screening Period Activities and Randomization - RP Cohort
During the screening period (interval of up to approximately  35 day s, starting from the 
signing of the informed consent/assent and extending up to visit 2, day  1),subjects should 
adhere to their usual therapi[INVESTIGATOR_014] (including FVIII therap y) prescribed b y the investigator.  All 
AEs, bleeds, and medications must be recorded in the Subject Diary  (issued at visit 1, 
Screening).
After stud y eligibility  has been confirmed, a nd prior to visit 2, day  1, subjects will be 
randomized.  Allocation of subjects to treatment assignments will be performed through an 
interactive voice or web -based response s ystem.  RP subjects will practice prophy laxis 
during both study  segments and wil l be randomly  assigned in a 1:1 ratio to 1 of 2 treatment 
sequences (AB or BA) defining the proph ylaxis regimens to be practiced for 12 months each 
during segments 1 and 2, respectivel y:
A: 45  5 IU/kg, administered twice perweek
B: 25 5 IU/kg, administe red every  other day

Moroctocog alfa (AF -CC) 
3082B2 -313-WW –(B1831001) 
Final Amendm ent 
10,02 October 2015
Page 38For regimen A, the interval between proph ylactic infusions should be 3 to 4 day s, and should 
not exceed 4 days.  For regimen B, the interval between proph ylactic infusions should be 
approximatel y 48 hours (eg, an appropriate dosing sche dule for Regimen B is as follows 
Monday , Wednesday , Friday , Sunday , Tuesday , Thursday , Saturday , Monday …etc). 
Randomization will be stratified b y hemophilia A severit y: FVIII activity  <1% or 1- 2% 
(central laboratory  screening result).  The randomizations will be performed as specified in 
the Study  Reference Manual.
15.1.5.
Study Visit 2 (Day 1) - Segment [ADDRESS_280268] will be notified by  [CONTACT_232272] 2 (day  1).  Visit 2 (day  1) should occur within approximately  35 day s after 
visit 1 (Screening).  Onl y subjects who have met the eligibility  criteria for the study  should 
have visit 2 (day  1).
This visit requires a [ADDRESS_280269] exogenous FVIII:C 
at the time of the visit.  Therefore, depending on the last FVIII dose before the beginning of 
the FVIII washout, an interval longer than [ADDRESS_280270] sustains a 
bleed requiring treatment during the 72-hour FVIII washout, the necessa ry treatment should 
be administered using the subject’s usual FVIII replacement product.  Once the bleed has 
been adequatel y treated, visit [ADDRESS_280271] be preceded by a new 
72-hour FVIII washout.
The subject will be examined, measured for weight (kilograms), have vital signs taken 
(including temperature [Celsius], blood pressure, pulse, and respi[INVESTIGATOR_1516]) , and will have blood 
samples collected for:
FVIII:C (central laboratory )
.
FVIII inhibitor (central laboratory ).
anti-FVIII antibod y (central laboratory ).
anti-CHO antibody  (central laboratory ).
anti-TN8.2 antibod y (central laboratory) .
At this visit, the subject will turn in his Subject Diary.  The investigator (or designee) will 
review the Subject Diary  with the subject, and inquire about and record AEs, bleeds, and use 
of medications.  In addition to the information obtained from those sources, the subject 
should be asked the following nonspecific question: “ How have you been feeling since your 
last visit? ”  Signs and symptoms should be recorded using standard medical terminology .
[IP_ADDRESS]. Pharmacokinetic Assessment (if Applicable) -Segment [ADDRESS_280272] Cohort
Please 
refer to Section 15.2 and study flowchart 2in Section 8 for PK -related study  
procedures.

Moroctocog alfa (AF -CC) 
3082B2 -313-WW –(B1831001) 
Final Amendm ent 
10,02 October 2015
Page 3915.1.5.2. Study Drug Dispensed -RP Cohort
Study  drug (moroctocog alfa [AF -CC] and accessory  supplies) will first be dispensed to the 
subje ct at this visit.  The investigator (or designee) will provide study  drug according to the 
subject’s treatment modality , prophy laxis, and using the subject’s weight recorded that day  
(see Study  Reference Manual for guidelines of dose selection based on the subject’s 
measured bod y weight; dispensed supplies also include supplies for treatment of an y bleeds).  
RP subjects will be following the protocol -defined regimen to which they  have been 
randomly  assigned (A or B), therefore the investigator (or designee) will review the assigned 
regimen, and information related to regimen escalation (criteria for, and subsequent action; 
see Section 15.3.3) with the subject.  For regimen A, the interval betwee n prophy lactic 
infusions should be 3 to 4 day s, and should not exceed 4 days.  For regimen B, the interval 
between proph ylactic infusions should be approximately
 48 hours (eg, an appropriate dosing 
schedule for Regimen B is as follows Monday , Wednesday , Friday, Sunday , Tuesday , 
Thursday , Saturday , Monday …etc).  All subjects will receive instructions for study  drug 
reconstitution and administration, and the appropriate materials (ie, Subject Diary ) and 
instructions to collect data on his home treatment (ie, infusions, bleeding events, response to 
infusions, etc).  All instructions given to the subject will be documented in the subject’s 
source document.  Subjects may  now commence treatment with study drug (moroctocog a lfa 
[AF-CC]).  For subjects who opt to participate in the PK assessment, moroctocog alfa 
(AF-CC) treatment should not commence until after the final PK sample collection 
(ie,32 hour collection).  ( NOTE : Treatment with study  drug may  occur before the final PK 
sample collection if a subject experi ences a bleeding epi[INVESTIGATOR_232215]; in the 
event that this occurs, the bleed is to be stabilized with study  drug.)  Onl y moroctocog alfa 
(AF-CC) may  be used for FVIII replacement therapy  from this point through the remainder 
of the treatment ph ase of this study ; the treatment phase starts at visit 2 (day  1) and ends at 
the Final Study  Visit (visit 19, month 24).
15.1.6. Subject Activities Between Successive Study Visits (Visit 2 Through Visit 11), 
and Activities of Study Contacts 4, 6, 8, and 10 -Segme nt 1 - RP Cohort
Subjects will use moroctocog alfa (AF -CC) for hemophilia A treatment (protocol- defined 
prophy laxis [including treatment of an y bleed, if necessary , during proph ylaxis]).  Subjects 
will document all of their infusions (dose, time of infusio n, and reason) and all bleeding 
epi[INVESTIGATOR_232216] .  In addition, subjects will record the efficacy  of a study  drug 
infusion given on- demand for treatment of a bleed using a 4 -point ordinal scale of 
“Excellent,” “Good,” “Moderate,” and “No Respo nse” in the Subject Diary (please refer to 
Section 18.1.3 fordescription of scale).  Subjects will also document any  AEs or use of 
concomitant medications in the Subject Diary .  Subjects will save used study  drug vials; used 
study  drug vials are returned at each study  visit.  Approximately  4 weeks (1 week) after 
study  visit 3, and approximately  6 weeks (±1 week) after stud y visits 5, 7, and 9, 
respectivel y, the investigator (or designee) will contact [CONTACT_423] b y telephone in order to 
collect information regarding the occurrence of any AEs, the use of concomitant medications, 
and study  compliance.  During these contacts, the investigator (or designee) will also review 
the subject’s hemophili a A treatment (ie, investigator -prescribed on -demand therapy , or 
protocol -defined proph ylaxis).  
The investigator (or designee) will also review information 
related to regimen escalation (criteria for, and subsequent action; see Section 15.3.3) with the 

Moroctocog alfa (AF -CC) 
3082B2 -313-WW –(B1831001) 
Final Amendm ent 
10,[ADDRESS_280273]’s prophylaxis regimen must be recorded; changes in the prophy laxis 
regime n should only  occur in the event that escalation criteria are met.  These study  contacts, 
following study  visits 3, 5, 7, and 9 are referred to as study  contacts 4, 6, 8, and 10, 
respectivel y. (Note : Study  contact [CONTACT_232273], if the subj ect or the investigator prefers ).
15.1.7. Study Visits 3, 5, 7, and 9 (Study Months 1, 3, 6, and 9) – Segment 1 -RP Cohort
Approximately  1, 3, 6, and 9 months after visit 2 (day  1), the subject will return to the clinic 
for study  visits 3, 5, 7, and 9, respectivel y.  If the study  visit occurs outside of the 
recommended stud y visit window (ie,  1 week) the reason must be documented in the 
subject’s source document.
These visits require a 72 -hour FVIII washout; thus, for subjects assigned to prophy laxis 
regimen B, an interruption in the every -other -day dosing frequency  is required.  The subject 
should not have exogenous FVIII:C at the time of the visit.  Therefore, depending on the last 
FVIII dose before the beginning of the FVIII washout, an interval longer than [ADDRESS_280274] sustains a bleed requiring treatment during the 72-hour FVIII 
washout, the necessary  treatment should be administered using moroctocog alfa (AF- CC).  
Once the bleed has been ade quatel y treated, the study  visit must be rescheduled, and must be 
preceded b y a new72-hour FVIII washout.
The subject will be examined, measured for weight (kilograms), have vital signs taken 
(including temperature [Celsius], blood pressure, pulse, and r espi[INVESTIGATOR_1516]) , and will have blood 
samples collected for:
FVIII:C (central laboratory )
.
FVIII inhibitor (central laboratory ).
anti-FVIII antibod y (central laboratory) .
The subject will turn in his used study  drug vials, account for all study  drug he has rece ived, 
and turn in his Subject Diary .  The investigator (or designee) will review the Subject Diary  
with the subject, and inquire about and record AEs, concomitant medications, or any  study  
drug infusions for efficacy  assessments.  In addition to the inform ation obtained from those 
sources, the subject should be asked the following nonspecific question: “How have you been 
feeling since your last visit? ”  Signs and sy mptoms should be recorded using standard 
medical terminology .  During the review, the investi gator (or designee) will inquire about 
study  compliance, review information related to less than expected therapeutic effect (LETE) 
(see Section 18.2 forcriteria), and will review the subject ’s hemophilia A treatment 
(ie,protocol -defined prophy laxis).  The investigator (or designee) will also review 
information related to regimen escalation (criteria for, and subsequent action; see 
Section
15.3.3) with the subject and will ensure that the criteria for regimen escalation had 
notbeen met.  In addition, any  change in a subject’s prophy laxis regimen must be recorded; 

Moroctocog alfa (AF -CC) 
3082B2 -313-WW –(B1831001) 
Final Amendm ent 
10,[ADDRESS_280275] Diary  will be issued.
15.1.8. Study Visit 11 (Study Month 12) - RP Cohort
Approximately  12 months after visit 2 (day  1), the subject will return to the clinic fo r study  
visit 11.  I f the study visit occurs outside of the recommended study visit window 
(ie,1 week), the reason must be documented in the subject’s source document.
For RP subjects, visit 11 (month 12) marks the subject’s completion of the first 12 -month 
moroctocog alfa (AF -CC) treatment period (segment 1).  Visit 11 (month 12) also marks the 
start of the second 12 -month moroctocog alfa (AF -CC) treatment period (segment 2) for 
these subjects.
This visit requires a 72 -hour FVIII washout; thus, for subje cts assigned to prophy laxis 
regimen B, an interruption in the every -other -day dosing frequency  is required.  The subject 
should not have exogenous FVIII:C at the time of the visit.  Therefore, depending on the last 
FVIII dose before the beginning of the FV III washout, an interval longer than [ADDRESS_280276] sustains a bleed requiring treatment during the 72-hour FVIII 
washout, the necessary  treatment should be administered using moroctocog alfa (AF- CC).  
Once the bleed has been adequa tely treated, visit [ADDRESS_280277] be 
preceded b y a new 72-hour FVIII washout.
The subject will be examined, measured for weight (kilograms) and height (centimeters), 
have vital signs taken (including temperature [Celsius], blood pressur e, pulse, and 
respi[INVESTIGATOR_1516]) , and will have blood samples collected for:
Hematology  panel (see Protocol Definitions; central laboratory ) .
Serum chemistry  (see Protocol Definitions; central laboratory ).
FVIII:C (central laboratory ).
FVIII inhibitor (central laboratory ).
anti-FVIII antibod y (central laboratory) .
anti-CHO antibody  (central laboratory ).
anti-TN8.2 antibod y (central laboratory).
The subjects will turn in their used study  drug vials, account for all study  drug received, and 
turn in their Subject Diary .  The investigator (or designee) will review the Subject Diary  with 
the subject, and inquire about and record AEs, concomitant medications, or any  study  drug 
infusions for efficacy  assessments.  In addition to the information obtained from those 

Moroctocog alfa (AF -CC) 
3082B2 -313-WW –(B1831001) 
Final Amendm ent 
10,[ADDRESS_280278] should be asked the following nonspecific question: "How have you been 
feeling since your last visit?"  Signs and sy mptoms should be recorded using standard 
medical terminology .  During the review, the investigator (or designee) will inquire about 
study  compliance, review information related to LETE ( see Section 18.2 for criteria ), and 
will review the subject’s hemophilia A treatment (ie, protocol -defined prophy laxis).  The 
investigator (or designee) will also review information related to regimen escala tion (criteria 
for, and subsequent action; see Section 15.3.3) with the subject and will ensure that the 
criteria for regimen escalation had not been met.  In addition, any change, that may  have 
occurred since the last study  contact (study  contact 10), in a subject’s prophy laxis regimen 
must be recorded; changes in the proph ylaxis regimen should only  occur in the event that 
escalation criteria are met.
[IP_ADDRESS]. Start of Segment 2 
-RP Cohort
RP subjects following 1 of the 2 protocol- defined regimens to which they  were randoml y 
assigned during the screening period ( see Section 15.1.4), will now crossover to the other 
protocol -defined regimen.
The investigator (or designee) will review the assigned proph ylaxis regimen, and information 
related to regimen escalation (criteria for, and subsequent action; see Section 15.3.3) with the
subject.  For regimen A, the interval between prophy lactic infusions should be 3 to 4 day s
, 
and should not exceed 4 day s.  For regimen B, the interval between prophylactic infusions 
should be approximatel y 48 hours (eg, an appropriate dosing schedule for Re gimen B is as 
follows Monday , Wednesday , Friday , Sunday , Tuesday , Thursday , Saturday , Monday …etc).  
The instructions given to the subject will be documented in the subject’s source document.
[IP_ADDRESS]. Study Drug Dispensed –Segment 2 -RP Cohort
Study  drug (moroctoc og alfa [AF -CC] and accessory  supplies) will be dispensed to the 
subject.  The investigator (or designee) will provide study  drug for proph ylaxis treatment 
(and for treatment of any bleeds) using the subject’s weight recorded that day (see Stud y 
Reference Manual for guidelines of dose selection based on the subject’s measured bod y 
weight).  The investigator will review instructions for study  drug reconstitution and 
administration with the subject.  The subject will also receive a new Subject Diary  and 
instructions to collect data on his home treatment (ie, infusions, bleeding events, response to 
infusions, etc).  The instructions given to the subject will be documented in the subject’s 
source document.
Subjects should now commence moroctocog alfa (AF -CC) prophy laxis according to the 
assigned regimen (A or B).  RP subjects following 1 of the 2 protocol -defined regimens to 
which they  were randomly  assigned during the screening period ( see Section 15.1.4), will
now crossover to the other protocol
-defined regimen.  These subjects will follow the assigned 
prophy laxis regimen for a 12- month period.  Onl y moroctocog alfa (AF -CC) study  drug may  
be used for FVIII replacement therap y during this 12- month pe riod (ie, through the 
remainder of the treatment phase of this study  which ends at the Final Study  Visit [visit 19, 
month 24]).

Moroctocog alfa (AF -CC) 
3082B2 -313-WW –(B1831001) 
Final Amendm ent 
10,[ADDRESS_280279] Activities Between Successive Study Visits (Visit 11 Through Visit 19), 
and Activities of Study Contacts 12, 14, 16, and 18 - Segment 2 -RP Cohort
Subjects should adhere to their assigned moroctocog alfa (AF -CC) prophylaxis regimen.  
Subjects should also use study  drug for the treatment of a bleed, if necessary .  Subjects will 
document 
all their infusions (dose, time of infusion, and reason) and all bleeding epi[INVESTIGATOR_232217] .  In addition, subjects will record the efficacy  of a study  drug infusion 
given on -demand for treatment of a bleed using a 4- point ordinal scale of “Excellent,” 
“Good,” “Moderate,” and “No Response” in the Subject Diary  (please refer to Section 18.1.3
, for description of scale).  Subjects will also document any  AEs or use of concomitant 
medications in the Subject Diary .  Subjec ts will save used study  drug vials (used study  drug 
vials are returned at each study  visit).  Approximately  6 weeks (1 week) after study  
visits 11, 13, 15 and 17, respectivel y, the investigator (or designee) will contact [CONTACT_232274], the use of 
concomitant medications, study  compliance, and to ensure that the criteria for regimen 
escalation had not been met ( seeSection 15.3.3 for criteria and subsequent action ).  The 
investigator (or designee) will also review the subject’s assigned prophy laxis regimen, and 
information related to regimen escalation with the subject during these contacts.  Any  change 
in a subject’s proph ylaxis regimen must be recorded; changes in the prophy laxis regimen 
should only  occur in the event that escalation criteria are met.  The study  contacts, following 
visits 11, 13, 15 and 17, are referred to as study  contacts 12, 14, 16, and 18, respec tively.  
(Note : Study  contact [CONTACT_232275] y scheduled clinic visit, 
if the subject or the investigator prefers) .
15.1.10. Study Visits 13, 15, and 17 (Months 15, 18, and 21) -Segment 2 -RP Cohort
Approximately  15, 18, and 21 mon ths after visit 2 (day  1), the subject will return to the clinic 
for study  visits 13, 15, and 17, respectivel y.  If the study  visit occurs outside of the 
recommended stud y visit window (ie, 
1 week) the reason must be documented in the 
subject’s source doc ument.
These visits require a 72 -hour FVIII washout; thus, for subjects assigned to prophy laxis 
regimen B, an interruption in the every -other -day dosing frequency  is required.  The subject 
should not have exogenous FVIII:C at the time of the visit.  Theref ore, depending on the last 
FVIII dose before the beginning of the FVIII washout, an interval longer than [ADDRESS_280280] sustains a bleed requiring treatment during the 72-hour FVIII 
washout, the necessary  treatment should be adminis tered using moroctocog alfa (AF -CC).  
Once the bleed has been adequatel y treated, the study  visit must be rescheduled, and must be 
preceded b y a new72-hour FVIII washout.
The subject will be examined, measured for weight (kilograms), have vital signs tak en 
(including temperature [Celsius], blood pressure, pulse, and respi[INVESTIGATOR_1516]) , and will have blood 
samples collected for:
FVIII:C (central laboratory )
.
FVIII inhibitor (central laboratory ).

Moroctocog alfa (AF -CC) 
3082B2 -313-WW –(B1831001) 
Final Amendm ent 
10,02 October 2015
Page 44anti-FVIII antibod y (central laboratory) .
The subject will turn in his used study  drug vials, account for all study  drug he has received, 
and turn in his Subject Diary .  The investigator (or designee) will review the Subject Diary  
with the subject, and inquire about and record AEs, concomitant medications, or any  study  
drug infusions for efficacy  assessments.  In addition to the information obtained from those 
sources, the subject should be asked the following nonspecific question: "How have you been 
feeling since your last visit?"  Signs and sy mptoms should be recorded us ing standard 
medical terminology .  During the review, the investigator (or designee) will inquire about 
study  compliance, review information related to LETE ( see Section 18.2 for criteria), an d 
ensure that the criteria for regimen escalation had not been met (see Section 15.3.3 for 
criteria and subsequent action).  The investigator (or designee) will also review the subject’s
assigned proph ylaxis regimen, and information related to regimen escalation with the subject.  
Any change in a subject’s prophy laxis regimen must be recorded; changes in the prophy laxis 
regimen should only  occur in the event that escalation criteria are met.
Additional study  drug will be dispensed as needed, and a new Subject Diary  will be issued.
15.1.11.
Final Study Visit (Visit 19, Month 24) - Segment 2 – RP Cohort
Approximately  24 months after visit 2 (day  1), RP subjects will return to the clinic for study  
visit 19 (month 24).  I f the study  visit occurs outside of the recommended study  visit window 
(ie, 1 week), the reason must be documented in the subject’s source document.
Visit 19 is the Final Study Visit; it coincides with the subject’s completion of the second 
12-month treatment period (segment 2), and marks the conclusion of the treatment phase of 
the study .  At the conclusion of the treatment phase, subjects will resume their usual FVIII 
replacement therap y and will not use study  drug.
This visit requires a [ADDRESS_280281] exogenous FVIII:C 
at the time of the visit.  Therefore, depending on the last FVIII dose before the beginning of 
the FVIII washout, an interval longer than [ADDRESS_280282] sustains a 
bleed requiring treatment during the 72-hour FVIII washout, the necessary treatment should 
be administered using moroctocog alfa (AF-CC).  Once the bleed has been adequatel y 
treated, visit [ADDRESS_280283] be preceded by  a new  72-hour FVII I 
washout.
The subject will be examined, measured for weight (kilograms), have vital signs taken 
(including temperature [Celsius], blood pressure, pulse, and respi[INVESTIGATOR_1516]) , and will have blood 
samples collected for:
CD4 cell count (central laboratory )
.
Hema tology  panel (see Protocol Definitions; central laboratory ) .
Serum chemistry  (see Protocol Definitions; central laboratory ).
FVIII:C (central laboratory ).

Moroctocog alfa (AF -CC) 
3082B2 -313-WW –(B1831001) 
Final Amendm ent 
10,02 October 2015
Page 45FVIII inhibitor (central laboratory ).
anti-FVIII antibod y (central laboratory) .
anti-CHO antibody  (central laboratory ).
anti-TN8.2 antibod y (central laboratory) .
The subject wil l turn in all study  drug vials ( used and unused ) and all unused diluent, 
account for all study  drug he has received, and turn in his Subject Diary .  The investigator (or 
designee) will review the Subject Diary  with the subject, and inquire about and record AEs, 
concomitant medications, or an y study drug infusions for efficacy assessments.  In addition 
to the information obtained from those sources, the subject should be asked the following 
nonspecific question: "How have you been feeling since your last vis it?"  Signs and 
symptoms should be recorded using standard medical terminology .  During the review, the 
investigator (or designee) will also inquire about study  compliance, and review information 
related to LETE ( see Secti on 18.2 for criteria ).  Any  change, that may  have occurred since 
the last study  contact (study  contact 18), in a subject’s prophy laxis regimen must be 
recorded; changes in the prophy laxis regimen should only  occur in the event that escalation 
criteria are met ( see Section 15.3.3 forcriteria ).
At the end of visit 19, the subject makes an appointment for a Final Study  Contact (visit 20) 
that must occur at least 28 d ays (+10 day s) after the Final Study  Visit (visit 19).
15.1.12.
Final Study Contact (Visit 20) – RP Cohort
At least 28 day s (+10 day s) after the Final Study  Visit (visit 19), the investigator 
(ordesignee) will contact [CONTACT_232276] i nformation regarding 
the occurrence of an y AEs and the use of medications.  I n addition, the subject should be 
asked the following nonspecific question: "How have you been feeling since your last visit?"  
Signs and sy mptoms should be recorded using standar d medical terminology .  Completion of 
this telephone contact [CONTACT_232258]’s participation in the study .  (Note : Final study  
contact [CONTACT_232277], if the subject 
or the investigator prefers ).
15.2. Study Procedures for Pharmacokinetic Assessment
Please also refer to study F lowchart 2 in Section 8, for an overview of PK -related study  
procedures.
Somesubjects will participate in a PK assessment.  This is optional for subjects who are 
<16years of age at the time of visit 2, who meet the additional PK eligibility  criteria outlined 
in Section
12.1, and who enroll at a stud y site participating in the PK assessments.  
Consenting, PK -eligible subjects will be enrolled sequentially  into the PK portion of the 
study .  Thus, if applicable, subjects will begin activities for the PK assessment as d escribed 
below (also refer to Section 8).  Subjects must be in a nonbleeding state for this assessment.

Moroctocog alfa (AF -CC) 
3082B2 -313-WW –(B1831001) 
Final Amendm ent 
10,02 October 2015
Page 46The procedures for visit 2, detailed previousl y in Section 15.1.5 for RP subjects 
(ie,examination and collection of weight, vital signs, AEs, medications, and blood samples), 
should occur within [ADDRESS_280284] a 
blood sample collected, within 2 hours before study  drug administration, for:
Hematology  panel (see Protocol Definitions; central laboratory ) .
An intravenous (IV) catheter (temporary ) will be inserted in [ADDRESS_280285] be drawn 
from the arm contralateral to the arm in which the infusion is administered.  If an indwelling 
catheter (eg, Port -A-Cath) is in place, it may be used for the infusion only.  In no case may  
blood samples be obtained via the catheter through which the study  drug was administered.
Heparin should not be used to flush indwelling catheters during PK study  drug administration 
or PK sampling.
The subject will receive a single 50  5 IU/kg , rounded to the nearest vial, intravenous (IV) 
infusion of moroctocog alfa (AF -CC), given over no more than [ADDRESS_280286]'s actual body weight as measured that day  (seeStudy  Reference Manual 
for specific guidelines for PK dose based on the subject’s measured bod y weight) .  The start 
and stop time of the infusion will be recorded.  The residual volume of dose remai ning in the 
tubing, if any , should be immediately  flushed into the subject as described in the Study  
Reference Manual.  Time 0 is the time when the study  drug infusion begins.
Blood samples for FVIII:C determinations, to be used for PK analy sis, will be dr awn at 
0.5hours (3 minutes), 8 hours ( 48minutes) , 24 hours ( 1 hour), 28 hours ( 1 hour), and 
32hours (1 hour) after the start of the stud y drug infusion (refer to study  flow chart in 
Section 8).  The blood sample to be drawn at [ADDRESS_280287] before (ie, within approximately  20 minutes of) the 0.5 and 24
-hour PK sample 
collection times, vital signs (including temperature [Celsius], blood pressure, pulse, and 
respi[INVESTIGATOR_1516]) will be collected.
Any AEs and concomitant medications should be recorded throughout the PK assessment in 
the subject’s source document.
If a subject experiences a bleeding epi[INVESTIGATOR_232218], the subject is to be 
stabilized with study  drug.  The samples collected should be processed as directed.

Moroctocog alfa (AF -CC) 
3082B2 -313-WW –(B1831001) 
Final Amendm ent 
10,[ADDRESS_280288] an accelerated Final Study  Visit .  At this accelerated visit, all data 
specified for the Final Study  Visit ( see Section 15.1.11 for RP subjects) will be collected.  
The accelerated Final Study
 Visit should occur, if possible , within [ADDRESS_280289]’s 
last infusion of study  drug.  A Final Study  Contact [CONTACT_232278] [ADDRESS_280290] developed a FVIII 
inhibitor after receiving study  drug if he has an inhibitor titer of 0.6 BU/mL in a sample 
assay ed at the central labora tory using the Nijmegen assay ; these criteria define a confirmed
FVIII inhibitor for this study .  In the event that a subject develops a confirmed FVIII 
inhibitor, the investigator will contact [CONTACT_1034]. The Sponsor and the investigator will 
determine whether the subject will remain inthe study  or be withdrawn from the study .
Subjects withdrawn from the study will complete the procedures of the Final Study  Visit and 
Final Study  Contact [CONTACT_103234] 15.1.11 and15.1.12 for RP subjects .  In addition 
to the Final Study  Visit procedures described in Section 15.1.11 for RP subjects, subjects 
with a confirmed FVIII inhibitor should be rechallenged , unless medicall y contraindicated, 
with a single moroctocog alfa (AF -CC) infusion of 50 5IU/kg at the Final Study  Visit, 
following the 72
-hour FVIII washout requir ed for this visit (see Study  Reference Manual for 
instructions regarding study  drug reconstitution, administration , and data recording).
All blood sample collections required at the Final Study  Visit (see Section 15.1.11 for RP 
subjects), as well as the phy sical examination and collections of weight and vital signs, will 
occur before the moroctocog alfa (AF -CC) infusion for rechallenge.  A blood sample wi ll be 
collected at 0.5 hours (± 3minutes) after administration of the rechallenge infusion and sent 
to the central laboratory  for FVIII: C anal ysis.  Vital signs (including temperature [Celsius], 
blood pressure, pulse, and respi[INVESTIGATOR_1516]) will be collected just before (ie, within approximately  
20 m inutes of) the 0.5 -hour sample collection.  Three (3) to 5 day s (inclusive of a 72- hour 
FVIII washout if possible) after the moroctocog alfa (AF -CC) infusion for rechallenge, blood 
samples will be collected for FVIII:C, FVIII inhibitor, and anti -FVIII anti body  testing at the 
central laboratory .  Samples collected for the rechallenge analy sis must be prepared and 
identified according to instructions provided in the Study  Reference Manual.  After at least 
[ADDRESS_280291], as described in Section 15.1.12 for RP subjects.
NOTE :All tests for FVIII:C and/or FVIII inhibitor performed at the local laboratory sh ould 
have duplicate samples from the same phlebotomy shipped to the central laboratory for 
analyses .  In cases of FVIII inhibitor development, these duplicate analyses will continue 
until the Final Study Contact .  Thus, a duplicate sample of all samples te sted at the local 
laboratory  for FVIII inhibitor development should also be sent to the central laboratory  for 
confirmatory  testing.  Aliquots of plasma samples will be stored in a -70°C or colder freezer.  
See Section 17.1 for additional discussion regarding FVIII inhibitor development.

Moroctocog alfa (AF -CC) 
3082B2 -313-WW –(B1831001) 
Final Amendm ent 
10,02 October 2015
Page 4815.3.3. Regimen Escalation
During proph ylaxis (segments 1 and/or 2), a subject’s proph ylaxis regimen will be escalated 
if criteria are met.  The criteria for regimen e scalation will be the occurrence of either of the 
following:
a.2 or more spontaneous (atraumatic) bleeds into major joints (such as elbow, ankle, or 
knee joint) and/or into other target joints over a 4 -week (28 -day) period in the 
absence of a confirmed FVIII inhibitor .
OR
b. 3 or more spontaneous (atraumatic) bleeds (consisting of joint bleeds and/or 
significant soft tissue/muscle or other site bleeds) over a 4 -week (28- day) period in 
the absence of a confirmed FVIII inhibitor.
Significant spontaneous bleeds are defined as those that lead to a transient or persistent loss 
of function.[ADDRESS_280292] to utilize the affected bod y part in usu
al activities be it on account of pain, 
associated swelling or limitation in motion.  This specification is intended to prevent regimen 
escalation based upon clinically insignificant or minor bleeding epi[INVESTIGATOR_1841] (eg, ecchy moses, 
epi[INVESTIGATOR_3940]). 
The investigator will review these criteria with the subject/caregiver at the time study  drug is 
first dispensed for protocol -assigned proph ylaxis treatment, during telephone contacts, and at 
study  visits.  I n the event that any  of the criteria for regimen escalation are met, the 
subject/caregiver must contact [CONTACT_82674], and the investigator will 
confirm that the subject has met criteria.  The subject’s treatment will be escalated to a higher 
intensity  prophy laxis regimen comprised of the most intensive components of both regimens 
A and B: 45  5 IU/kg, administered every other day .  The investigator will provide the 
subject/caregiver with instructions for the new, more intense prophy laxis regimen.  The 
subject will now follow the protocol -assigned regimen escalation, and arrangements for 
adequate stud y drug supplies will be made.  Further proph ylaxis regimen escalations will be 
prescribed b y the investigator with each recurrence of escalation criteria.  The subject will 
follow the assigned regimen( s) until the respective 12- month period of prophy laxis with 
study  drug has been completed (segment 1 or 2); the 12-month period is inclusive of 
treatment time on all the prophylaxis regimens assigned during the respective study  segment.
15.3.4. Unplanned, Required Surgery
As indicated, major surgery  or orthopedic surgery planned to occur within the period 
following signing of the consent/assent form to the Final Study  Contact (ie, during the course 
of this study ) is an exclusion criterion for this study and onl y required minor surgery , or 
major/orthopedic surgical procedures which were unplanned at the time of signing the 
consent/assent form, may be allowed during the course of this study . 
Major surgical intervention- surgery  involving open abdominal, intracranial and 
orthopedic procedures, including sy novectomies and liver biopsies. Retroperitoneal, 

Moroctocog alfa (AF -CC) 
3082B2 -313-WW –(B1831001) 
Final Amendm ent 
10,[ADDRESS_280293] the Sponsor’s phy sician clinician.
Minor surgical intervention -surgery  that includes laparoscopic abdominal procedures 
such as laparoscopic cholecy stectomies or laparoscopic appendectomies.  Central 
venous catheter placement is also considered minor surgery .  For other minor 
surgeries contact [CONTACT_1034]’s phy sician clinician.
In the event that a minor surgery  or an unplanned major or orthopedic surgery  is required, the 
investigator will contact [CONTACT_1034]’s clinician.  The clinician will determine w hether the 
subject will remain on the study  or be withdrawn.  If withdrawn, the subject should follow 
procedures required for all withdrawn subjects (see Section 15.3.1 ).  Subjects who remain on 
the study  will temporarily  cease their current study  drug treatment regimen (ie, 
investigator -prescribed on- demand therap y or protocol -assigned proph ylaxis), and will 
instead receive stud y drug in bolus injection, as prescribed b y the investigator, to a chieve and 
maintain normal hemostasis through the surgical period.  Administration of study drug b y 
continuous infusion will not be allowed during surgery  or during the post surgical wound 
healing period. Moroctocog alfa (AF -CC) study  drug will be the onl y FVIII replacement 
product used during the surgical period. 
The surgical period includes pre- , intra -, and postoperative periods; the surgical period begins 
with the administration of an y preparatory  study  drug infusion for the surgery , and ends 
when the subject has recovered and is read y to resume his investigator- prescribed on -demand 
therap y or protocol -assigned prophy laxis with moroctocog alfa (AF -CC).  The investigator 
should refer to the Stud y Reference Manual for dosing guidelines for surgery.  Afte r 
reviewing the dosing guidelines for surgery  provided in the Study  Reference Manual, the 
investigator will designate the appropriate stud y drug dose, and treatment duration for the 
surgical period, and should inform the Sponsor’s clinician in advance.  Inaddition to any  
AEs and concomitant medications (including an y transfusions), the administration time and 
dose of all study  drug infusions will be recorded during the surgical period.  The subject’s 
estimated blood loss and any  nonpharmacological treatmen ts will also be reported.
Samples for FVIII:C measurements will be collected within 15 to 30 minutes before the 
preoperative moroctocog alfa (AF -CC) infusion; approximately  30 minutes after completion 
of the preoperative infusion (and before the first surgical incision); just before an y 
intraoperative infusion; approximately  30 minutes after completion of any  intraoperative 
infusion; and daily  during the in- hospi[INVESTIGATOR_307], postoperative period (ie, FVIII trough levels to be 
obtained before an infusion).  The time of the collection of samples for FVIII:C measurement 
will be recorded as well as the time of infusion of all doses.  NOTE :During the surgical 
period, all tests for FVIII:C and/or FVIII inhibitor performed at the local laboratory should 
have duplicate sam ples from the same phlebotomy shipped to the central laboratory for 
analyses .
Subjects will resume study  drug treatment, as prescribed by  [CONTACT_70385] (for on -demand 
therap y) or as defined b y their protocol -assigned regimen (for prophy laxis), followi ng the 

Moroctocog alfa (AF -CC) 
3082B2 -313-WW –(B1831001) 
Final Amendm ent 
10,02 October 2015
Page 50surgical period.  The surgical period will not count as time on the treatment periods of this 
study ; as such, stud y visits may need to be rescheduled accordingly.  For subjects whose 
surgical period exceeds 4 weeks, the Sponsor’s clinician will be c ontacted to discuss the 
suitability  of the subject’s continued participation in the study .
15.4. Total Volume of Blood Collected
For each subject who participates in the study , the total volume of blood collected over the 
study  period is detailed in the following table. 
Study Participation Blood Volume ( mL)
Study Visit/Contact [CONTACT_5883] [ADDRESS_280294] + PK 20 42a9 9 9 9 18 9 9 9 20 163
Abbreviations: RP Subject = Routine Prophylaxis treatment d uring segment 1 followed by [CONTACT_232279] 2; RP Subject + PK = Routine Prophylaxis treatment and Pharmacokinetic Assessment during segment 1 
followed by [CONTACT_232280] 2.
a. 42 mL total.  Approxi mately 28 mL on day 1 of PK assessment and 14 mL on day 2 of PK Assessment (Visit 2).
16.TEST ARTICLE AND ADM INISTRATION
Study  drug, moroctocog alfa (AF -CC), will be labeled according to local regulations.  The 
Sponsor will not ship clinical supplies until a signed approval letter from the I RB/IEC has 
been received anda contractual agreement has been signed b y the Sponsor and the study  site.
16.1. Moroctocog alfa (AF -CC) Administration for Pharmacokinetic Assessment
A single IV infusion of study drug at a dosage o f 50 5 IU/kg rounded to the nearest 
complete vial, will be administered over no more than [ADDRESS_280295]'s actual body  weight 
as measured on the day  of study  drug administration ( see Study  Reference Manual for 
specific guidelines for PK and recovery  dose based on the subject’s measured body  weight).  
The time of study  drug reconstitution will be recorded.  The start and stop time of the 
infusion will be recorded.
16.2. Moroctocog alfa (AF -CC) Administration for Rechallenge
In addition to the Final Study  Visit procedures described in Section 15.1.11 for RP subjects, 
subjects with a confirmed FVIII inhibitor s
hould be rechallenged, unless medically  
contraindicated, with a single moroctocog alfa (AF -CC) study  drug infusion of 50 ±5IU/kg 
at the Final Study  Visit, following the 72-hour FVIII washout required for this visit (see 
Study  Reference Manual for instruct ions regarding study  drug reconstitution, administration, 
and data recording).
16.3. Moroctocog alfa (AF -CC) Administration for Hemophilia A Treatment
In total, RP subjects will use moroctocog alfa (AF -CC) study  drug, in an open- label manner, 
for a 24- month peri od.  In segment 1, all subjects will use moroctocog alfa (AF -CC) 
according to 1 of 2 randomly  assigned 
proph ylactic regimens.  Segment 1 for RPsubjects 

Moroctocog alfa (AF -CC) 
3082B2 -313-WW –(B1831001) 
Final Amendm ent 
10,02 October 2015
Page 51will be 12 months in duration.  All subjects will then use moroctocog alfa (AF -CC) for 
prophy laxis duri ng segment 2, as specified in Section 16.3.2.  Prophy laxis subjects will cross 
over to the other protocol -assigned proph ylaxis regimen during segment 2.  During 
prophy laxis, subjects will also use moroctocog alfa (AF -CC), as needed, for the treatment of 
bleeds (ie, on-demand).  SeeSection 16.3.1 and 16.3.2 foradministration guidelines and 
recommendati ons for on- demand and proph ylaxis dosing, respectivel y.
Moroctocog alfa (AF -CC) study  drug will be administered as a bolus intravenous infusion. If 
an indwelling catheter (eg, Port-A- Cath) is in place, it may  be used for moroctocog alfa 
(AF-CC) study  drug infusions, when appropriate.
16.3.1. Moroctocog alfa (AF -CC) Administration for On -Demand Treatment of 
Breakthrough Bleeds
All bleeding epi[INVESTIGATOR_232219] (on -demand) at the discretion of the 
caregiver/investigator.  Treatment guidelines, based on current recommendations for 
on-demand treatment with the licensed product Xyntha®, are provided in Appendix 1.  
A
subject’s specific circumstances should be considered when determining a specific dose.  
The dose will be prepared using the actual potency on the label of the study drug to be 
administered and the subject's most recent actual body  weight as measured during the study .
16.3.2. Moroctocog alfa (AF -CC) Administration for Prophylaxis
Subjects will be advised to routinely  administer the proph ylaxis dose in the morning, in 
advance of their day ’s activities.  The dose will be prepared using the actual potency  on the 
label of the stud y drug to be administered and the subject's most recent actual body  weight as 
measured during the study.  See Study  Reference Manual for guidelines of dose selection 
based on the subject’s measured bod y weight.
Subjects will use moroctocog alfa (AF -CC) for prophy laxis according to the assigned 
regimen, A or B:
A: 45 5 IU/kg, administered twice per week
B: 25 5 IU/kg, administered every  other day
For regimen A, the interval between proph ylactic infusions should be 3 to 4 day s, and should 
not exceed 4 days.  For regimen B, the interval between proph ylactic infusions should be 
approximatel y 48 hours (eg, an appropr iate dosing schedule for Regimen B is as follows 
Monday , Wednesday , Friday , Sunday , Tuesday , Thursday , Saturday , Monday …etc). 
The dosage and dosing frequency  of these regimens are consistent with ReFacto and 
moroctocog alfa (AF -CC) clinical data, and with recommendations for prophy lactic dosing in 
the literature .3,12,19,20,21  (See Study  Reference Manual for specific dose selections for 
regimens A and B based on the subject’s measured body  weight).  A subject’s treatment will 
be escalated to a more inte nsive proph ylaxis regimen (45 5 IU/kg, administered every  other 
day, initiall y, and if dose escalation criteria are met while on this more intensive regimen the 
subsequent regimen escalation will be investigator
-designated) if criteria justify ing regimen 

Moroctocog alfa (AF -CC) 
3082B2 -313-WW –(B1831001) 
Final Amendm ent 
10,02 October 2015
Page 52escalation are met (see Section 15.3.3).   Guidance for proph ylaxis treatment is offered in the 
investigator’s brochure.
16.4. Formulation, Packaging, and Labeling
The study  drug, moroctocog alfa (AF -CC), is formulated as a sterile, nonpy rogenic, 
lyophilized powder preparation for IV injection.  Study  drug will be available in single -use 
vials containing the labeled amount of actual FVIII activity  (IU).  Each vial of study  drug 
contains nominally  250 IU, 500 IU, 1000 IU, or 2000 IU per vial.
16.5. Storage and Stability
Moroctocog alfa (A F
-CC) as packaged: Study  drug should be stored under refrigeration at a 
temperature of 2 °C to 8 °C (36 °F to 46 °F).  I t is stable for up to 3 months at 25 °C.The 
product should not be returned to refrigeration once it has been stored at 25 °C. Freezing of 
diluent or study  drug should be avoided to prevent damage.  The stud y drug should be stored 
to protect from light.  Study  drug should not be used after the expi[INVESTIGATOR_232220].
Investigators and site staff are reminded to check temperatures dail yand ensure that 
thermometers are working correctly  as required for proper storage of investigational 
products. These include thermometers for both the room storage and refrigerator storage.
Deviations from the storage requirements, including any  actions taken, must be documented 
and reported to the Sponsor. Once a deviation is identified, the study  drug must be 
quarantined and not used until the Sponsor provides documentation of permission to use the 
study  drug.
Moroctocog alfa (AF -CC) after reconstitut ion: The reconstituted moroctocog alfa (AF- CC) 
solution does not contain a preservative and should be used within 3 hours after 
reconstitution.  The reconstituted solution should not be refrigerated. 
16.6. Preparation
The investigator (or designee) should follo w specific reconstitution and administration 
procedures detailed in the Study  Reference Manual for study  drug preparation during the 
study . Caregivers should follow the specific reconstitution and administration procedures 
provided b y the investigator dur ing the study .
16.7. Drug Accountability
The US Food and Drug Administration (FDA) and other regulatory  agencies require 
accounting for the disposition of all investigational drugs received b y each study  site.  
Information on drug disposition required by  [CONTACT_232281], date 
administered, quantity  administered, and the subject to whom the drug was administered.  
The investigator is responsible for the accounting for all unused stud y drug and diluent and 
all used study  drug.  ( NOTE : Used diluent syringes will not be returned for test article 
accountability  due to the potential risk of blood contamination.  Therefore, each returned 
study  drug vial indirectly accounts for each diluent sy ringe used by  [CONTACT_423]).  Study  drug 
may not be given to nonstudy  patients under an y circumstances.

Moroctocog alfa (AF -CC) 
3082B2 -313-WW –(B1831001) 
Final Amendm ent 
10,[ADDRESS_280296] be maintained either in the pharmacy or 
in another area approved by  [CONTACT_941] S ponsor’s monitor.  Drug accountability  will be reviewed b y 
a monitor during routine monitoring visits and interim drug returns will be performed as 
needed.  Each time a dose is prepared (for the PK assessment) or vials are dispensed for a 
subject, the following information must be recorded: the subject’s stud y number, the number 
of vials dispensed, the date dispensed, the number of the lot from which the dose was 
prepa red, and the initials of the person preparing the dose. The doses prepared for subjects at 
the study  site for the PK assessment will be documented on a worksheet to be kept at the 
study  site.
The investigator (or designee) will instruct each subject or pa rent/legal acceptable 
representative to whom drug is dispensed, to return used study  drug vials at each stud y visit, 
and to return all study drug vials (used and unused) and all unused diluent syringes at the 
Final Study  Visit.
At the termination of the st udy, a final drug accountability  review and reconciliation must be 
completed and an y discrepancies must be investigated and their resolution documented. 
All used and unused study  drug vials and all unused diluent sy ringes may  be returned to the 
Sponsor.  Alternatively , all used and unused study  drug vials and unused diluent sy ringes 
may be destroy ed at site, per the local requirements, after the site and S ponsor have 
performed drug accountability .
16.8. Subject Compliance
The investigator or the Sponsor’s clinic ian may  withdraw a subject if he or she decides that a 
subject’s noncompliance is damaging to the study  or the subject’s best interests.  No 
predetermined percentage of missing vials or data will define a subject as “noncompliant.”  
The final study  report will document and report the impact of extensive noncompliance on 
study  conclusions.  Vial counts, Subject Diaries, and verbal information will be used to 
determine subject compliance.  Subjects who are withdrawn for noncompliance or an y other 
reason will have an accelerated Final Study  Visit.  All data specified in Section 15.1.[ADDRESS_280297] 28 day s after the Final Study  Visit, as 
described in Section 15.1.12 for RP subjects.
17.SAFETY
The Sponsor may  stop the study  for any  reason; the reason for study  cessation will be 
documented.
This study  will use an External Data Monitoring Committee (E -DMC) .  The E -DMC will 
periodicall y review data from the study to ensure subje ct safet y according to the Charter. 
The E- DMC includes phy sicians experienced in the management of hemophilia who are not 
investigators in the study, including at least one who is also experienced in the treatment of 

Moroctocog alfa (AF -CC) 
3082B2 -313-WW –(B1831001) 
Final Amendm ent 
10,[ADDRESS_280298] udy drug if he has a titer of ≥0.6 BU/mL  in a sample assay ed at the 
central laboratory using the Nijmegen assay ; these criteria define a confirmed FVIII inhibitor 
for this study .  Confirmed FVIII inhibitors will be further categorized as low titer or high 
titer.  L ow-titer inhibitors are defined as those inhibitors with titer sbetween 0.6 to <5 B U/mL  
in a sample assay ed at the central laboratory  using the Nijmegen assay .  High -titer inhibitors 
are defined as those inhibitors with a titer of 5 BU/mL  assay ed at the central laboratory  
using the Nijmegen assay .  If a FVIII inhibitor resolves (by  [CONTACT_232282] ) at or before a subject’s final assessment it will be further classified as transient.
Investigators must report all FVIII inhibitors in the same expedited manner as outlined for 
serious adverse events (SAEs; see Section 26.13.1 ).  The Sponsor will report all confirmed 
FVIII inhibitors to regulatory  authorities in the same manner as unexpected, related SAEs.
If a subject has a local laboratory  assay  that is considered positive for FVIII inhibitor b y the 
investigator in spi[INVESTIGATOR_232221] a negative central laboratory  result, or the investigator considers the 
subject to have developed a FVIII inhibitor for other reasons based on clinical grounds 
(although all suspec ted FVIII inhibitors should also be supported by  [CONTACT_232283] ; the 
investigator may  perform additional laboratory  tests for FVIII inhibitor as appropriate in his 
medical judgment
), then the finding will be reported in the manner of and recorded as a n 
SAE.  Reports or assay s received b y the Sponsor, which are suggestive of a FVIII inhibitor, 
will be confirmed b y the study ’s central laboratory before communication with regulatory  
authorities.  I n addition, for purposes of the anal yses of this study , any FVIII inhibitor report 
not confirmed by [CONTACT_2237] (ie, s ample did not have a titer of 0.6 BU/mL  by [CONTACT_232284] ) will count as an SAE, but will not count as a FVIII inhibitor. 
In the event that subjects develop a confirmed FVIII inhi bitor, the investigator will contact 
[CONTACT_1034]. The Sponsor and the investigator will determine whether the subject will 
remain in the study  or be withdrawn from the study . Subjects withdrawn from the study  will
complete the procedures of the Final Stu dy Visit and Final Study  Contact [CONTACT_232285]
15.1.11 and 15.1.12.

Moroctocog alfa (AF -CC) 
3082B2 -313-WW –(B1831001) 
Final Amendm ent 
10,02 October 2015
Page 55FVIII inhibitor development is a safet y variable for this study .  The incidence of FVIII 
inhibitor (ie, number of subjects with confirmed FVIII inhibitor development) will be 
reported.
17.2. Antibodies to Moroctocog alfa (AF- CC) Components
Patient serum samples will be collected and tested for the development of antibodies (both 
neutralizing and nonneutralizing) to moroctocog alfa (AF -CC), antibodies to CHO cell 
proteins derived from the cell line used in manufacture of moroctocog alfa (AF- CC), and 
antibodies to TN8.2, the affinity
 ligand used in purification of moroctocog alfa (AF -CC), 
using a validated ELISA.
18.EFFICACY
Specific efficacy  variables for this study  are listed in Section 22.2.  The following describes 
the collection of some variables in
detail.
18.1. Bleeding
The incidence of bleeding treated with FVIII replacement infusion(s) will be obtained from 
Subject Diaries and medical records.  Where relevant, investigators (or designee) and 
monitors will ensure that there is consistency  between the subject’s medical record and/or 
Subject Diaries and the electronic case report forms ( eCRFs) .  Such bleeding epi[INVESTIGATOR_232222] a bleed may  be 
reported as an AE if appropriate (eg, a fracture).  In the rare instance in which a bleeding 
epi[INVESTIGATOR_232223] a Serious Adverse Event, then the bleeding epi[INVESTIGATOR_232224]. Only  bleeding epi[INVESTIGATOR_232225] o n the AE case report form ( CRF )page.  If the bleeding epi[INVESTIGATOR_232226], then in addition to recording the bleed 
event on the AE eCRF, the bleed event should also be recorded on the Bleed log as there is 
informatio n captured on the Bleed log that is not captured on the AE eCRF ( eg,infusion 
information and response to study  drug).
Both spontaneous bleeding epi[INVESTIGATOR_72805].
18.1.1. Types of Bleeding
For the purposes of this study , ableed treated with study  drug will be classified as either 
spontaneous or traumatic.  The subject’s diary  or medical record will serve as the source 
document for bleeding epi[INVESTIGATOR_71260] .  Investigators (or designee) and/or monitors 
will review the Subject Diary  and medical records to assist in classification if necessary .  The 
criteria for spontaneous and traumatic bleeds are described below.
Spontaneous Bleeding Epi[INVESTIGATOR_1841] : Bleeding epi[INVESTIGATOR_71261] a 
subject records a bleeding event when there is no known contributing factor such as definite 
trauma, antecedent “strenuous” activity , or “overuse”.  The determination of “strenuous” or 
“overuse” is at the discretion of the subject/caregiver/investigator.  For example, if a subject 
were to wake up in the morning and note he was bleeding, a “spontaneous” bleed would be 
recorded.  Target joints can have spontaneous bleeding epi[INVESTIGATOR_1841].  Incidences of spontaneous 

Moroctocog alfa (AF -CC) 
3082B2 -313-WW –(B1831001) 
Final Amendm ent 
10,02 October 2015
Page 56bleeding epi[INVESTIGATOR_232227] (see Section 15.3.3).  
For this purpose, spontaneous bleeds are further categorized as “ significant ”.  Significant 
spontaneous bleeds are defined as those that lead to a transient or per sistent loss of function 
(seeSection
15.3.3).
Traumatic Bleeding Epi[INVESTIGATOR_1841] : Bleeding epi[INVESTIGATOR_72802] a 
subject records a bleeding event when there is a known or p resumed reason for the bleed.  
For example, if a subject were to exercise strenuously  and then have a bleed in the absence of 
any obvious injury , the bleed would be recorded as a traumatic bleed.  Target joint bleeding 
epi[INVESTIGATOR_71266] a known action led to bleeding into the joint.
18.1.2. Location of Bleeds
For the purposes of this study , when subjects report a bleed treated with study  drug, the 
location of the bleed should be recorded in the Subject Diary  or medical record.  Bleeds will 
be reported as occurring in 1 of the following locations: joint, muscle/soft tissue, or other.  
Each individual location of multiple -site bleeds will be reported.  For joint bleeds, the 
specific joint will be reported.  Parameters to identify
 joint bleeds include: pain on joint 
motion, limitation of motion, and visible swelling of joint.
18.1.3. Treatment of Bleeds
Typi[INVESTIGATOR_897] , a bleed would be treated with an (on- demand) infusion of study  drug.  The 
specific treatment with study  drug is at the discretion of the subject/caregiver/ investigator but 
all doses and infusions of study  drug will be recorded and reported.
The subject/caregiver/investigator will assess efficacy  of study  drug in treating a bleed by  
[CONTACT_232286] 4
-point On- Dem and 
Hemostasis Efficacy  Rating Scale, described below.  The 4-point response scale for 
on-demand treatment of a bleeding epi[INVESTIGATOR_1865], is defined as follows:
Excellent : Definite pain relief and/or improvement in signs of bleeding starting within 
8hours after a n infusion, with no additional infusion administered.
Good : Definite pain relief and/or improvement in signs of bleeding starting within 
[ADDRESS_280299] one additional infusion administered for 
complete resolution of the bleeding e pi[INVESTIGATOR_1865]. 
or,
Definite pain relief and/or improvement in signs of bleeding starting after 8 hours 
following the infusion, with no additional infusion administered.
Moderate : Probable or slight improvement starting after [ADDRESS_280300] one additional infusion administered for complete resolution of 
the bleeding epi[INVESTIGATOR_1865].

Moroctocog alfa (AF -CC) 
3082B2 -313-WW –(B1831001) 
Final Amendm ent 
10,02 October 2015
Page 57No Response : No improvement at all between infusions or during the [ADDRESS_280301]
All bleed and study  drug infusion response data will be reported and anal yzed (see 
Section s 22.2 and 22.5.3).  The following text describes criteria defining a specific subset of 
these data that will also be reported and referred to “Less than expected therapeutic effect”.
“Less than expected therapeutic effect” (LETE) is an efficacy  variable of this study .  LETE 
can occur in [ADDRESS_280302] records 2 successive “ No Response ” 
ratings after [ADDRESS_280303] been 
administered within 24 hours ( 24 hours) of each other for treatment of the same bleeding 
event in the absence of confounding factors (described below).  Therefore, L ETE in the 
on-demand setting is based on the response to treatment of a bleed.  The only  confounding 
factors are as follows:
Known presence or subsequent identification of a FVIII inhibitor .
Known inad equate dose for the ty pe and/or severity  of bleed in the opi[INVESTIGATOR_1070] .
Delay  of greater than 4 hours between onset of bleed to infusion .
Delay  of greater than 24 hours before administration of a follow- up infusion .
Known compromised study  drug.
Faulty  administration of study  drug .
The subject has an underly ing, predisposing condition responsible for the bleed in the 
opi[INVESTIGATOR_871] (eg, kidney  stones or use of medications known to impair 
platelet function, such as aspi[INVESTIGATOR_119162] s).
For the purposes of this study , LETE in the on -demand setting will be summarized only  from 
eCRFs.  I n the absence of identified confounding factors, monitors will query  a site if 
2
“NoResponse ” ratings occur for 2 infusions which are given within 24 h ours ( ≤24 hours) 
for the same bleed and LETE is not noted.
Less than Expected Therapeutic Effect in the Prophylaxis Setting

Moroctocog alfa (AF -CC) 
3082B2 -313-WW –(B1831001) 
Final Amendm ent 
10,02 October 2015
Page 58LETE occurs in the prophy laxis setting if there is a spontaneous bleed within 48 hours 
(
≤ 48 hours) after a regularly  scheduled prop hylactic dose of study  drug (which was not used 
to treat a bleed) in the absence of confounding factors.  Therefore, LETE in the proph ylaxis 
setting is the occurrence of a bleed.  The onl y confounding factors are as follows:
Known presence or subsequent id entification of a FVIII inhibitor.
Known inadequate prophy lactic dose (ie, a dose less than that prescribed in subject’s 
regimen) .
Known lack of adherence to the prescribed prophylaxis regimen .
Bleed occurs in a target joint identified at the start of the study .
Known compromised study  drug .
Faulty  administration of study  drug .
The subject has an underly ing, predisposing condition responsible for the bleed in the 
opi[INVESTIGATOR_871] (eg, kidney  stones or use of medications known to impair 
platelet f unction, such as aspi[INVESTIGATOR_49267]) .
For the purposes of this study , LETE in the prophy laxis setting will be summarized only  
from eCRFs.  I n the absence of identified confounding factors, monitors will query  a site if a 
spontaneous bleed within 48 hours (≤ 48 hours) of a proph ylactic dose is recorded and LETE 
is not noted.
Less than Expected Therapeutic Effect (Low Recovery)
LETE can also be lower than expected recovery  of FVIII in the opi[INVESTIGATOR_232228].  There are no planned 
recovery  measurements outside the PK assessment that subjects may  undergo at study  start.  
During the course of this study , additional recovery  measurements should be done onl y for 
assessment of a possible F VIII inhibitor.  ( NOTE :During the treatment phase of the study, 
all tests for FVIII:C and/or FVIII inhibitor performed at the local laboratory should have 
duplicate samples from the same phlebotomy shipped to the central laboratory for analyses.)   
Therefo re, LETE (Low Recovery ) can happen only  if a recovery  measurement is performed 
for clinical management of a subject and an inhibitor is not confirmed b y the central 
laboratory .  The onl y confounding factors for low recovery  are as follows:
Known presence o r subsequent identification of a FVIII inhibitor .
Known compromised study  drug .
Faulty  administration of study  drug .

Moroctocog alfa (AF -CC) 
3082B2 -313-WW –(B1831001) 
Final Amendm ent 
10,02 October 2015
Page 5919. PHARMACOKINETICS 
19.1. Pharmacokinetic Analysis
FVIII:C will be anal yzed by  a central laboratory using a one - stage method (mnemonic 
CB-0052).  U sing a sample volume of 0.5 mL , the range of quantitation is 
0.0100-0.8300 IU/mL.  The upper limit of quantitation is slightly  variable and depends upon 
the potency  of the lot of calibrator.  Stability  of the samples has been shown for 3 freeze/thaw 
cycles.  The coefficient of variations for precision of the calibrators in method development 
was less than 12.4% and the accuracy
 ranged between 89 and 115% of the expected 
amount.22
19.2. Pharmacokinetic Methods
The plasm a FVIII activity (FVIII: C) -versus- time curves after administration of moroctocog 
alfa (AF -CC) will be characterized, using standard noncompartmental methods.  FVIII:C at 
0.5hours after the start of study  drug infusion (C 0.5 hr) will be directly  determine d from the 
observed FVIII:C data.  The terminal- phase disposition (elimination) rate constant ( z) will 
be estimated by [CONTACT_232287] -linear phase of the FVIII:C -versus- time curve.  
The terminal phase half -life (t ½) will be calculated as:
t½= ln2 /  z
The areas under the FVIII:C -versus
-time curves (AUC t) and under the moment curve 
(AUMC t) to last measurable activity  (Ct) will be calculated using the trapezoidal method. 
The area under the curve from 0 to infinity  (AUC) will be estimated a s:
AUC= AUC t+ C t/ z
Similarly , area under the moment curve from 0 to infinity (AUMC ) will be estimated as:
AUMC = AUMC t+ [(C tt) / z] + [C t/ (z)2]
where, t is the time corresponding to the last measurable C t.
The clearance (CL) will be calcula ted as:
CL = Dose/AUC 
where, Dose = IU/kg of study  drug administered.
The mean residence time (MRT) will be calculated as:
MRT = AUMC /AUC-TI/2
where, T I is the duration of infusion.
The volume of distribution at stead y state (V ss) will be calculated a s:

Moroctocog alfa (AF -CC) 
3082B2 -313-WW –(B1831001) 
Final Amendm ent 
10,02 October 2015
Page 60Vss= CL  MRT.
Incremental recovery , is estimated using the following formula:
Incremental recovery  = (C 0.5 hr-
C0)/Dose
where,
C0=  FVIII:C at time 0 (time before start of stud y drug infusion)
Dose = IU/kg of study  drug administered.
The FVIII:C conce ntrations measured in this study may  be combined with similar data from 
other studies to perform a population pharmacokinetic anal ysis using nonlinear mixed effects 
modeling (NONMEM).
20.PHARMACODYNAMICS
There are no planned pharmacodynamic evaluations. 
21.LABO RATORY DETERMINATION S
Samples for required assay s may  be collected according to the procedures at the clinical trial 
study  site.  Samples taken for the central laboratory  will be collected according to the 
schedule outlined in Section 7, 8and 15of this protocol.  Sample collection, storage, and 
shippi[INVESTIGATOR_232229].  
All clinically  important abnormal laboratory  test values identified after study  drug 
administration will be followed until the condition stabilizes or until the end of the subject’s 
participation in the study; any  clinically  important abnormal laboratory  test value should be 
reported as an AE (or SAE if appropriate, see Section s 26.[ADDRESS_280304] 
findings as AEs and 26.13.1 for SAE criteria).
22.STATISTICS
Additional details of the anal ysis will be provided in the statistical analy sis plan and/or the 
clinical study  report.  This may  include details of missing, and if applicable, unused and 
spurious data.  Deviations from the statistical plan will be reporte d in the clinical study  
report.
Safety  and efficacy  analyses for the OD cohort (on -demand therap y in segment 1, followed 
by [CONTACT_232288] 2), will be done independently  from the 
analyses for the RP cohort (randomized to follow prophy laxis regimens in both 
segments 1and 2).  PK characterization will be presented for all subjects (in either cohort) 
who provided PK data.  In addition, select tables will be provided for all subjects in the 
study , regardless of cohort.

Moroctocog alfa (AF -CC) 
3082B2 -313-WW –(B1831001) 
Final Amendm ent 
10,02 October 2015
Page 6122.1. Safety Var iables
Incidence of AEs (b y severity and b y relationship to moroctocog alfa [AF -CC]) .
Incidence of confirmed FVIII inhibitor development .
Incidence of development of antibodies to moroctocog alfa (AF- CC), CHO cell 
proteins, and TN8.2 .
22.2. Efficacy Variables
Annualized bleed rate (ABR) .
Number of moroctocog alfa (AF -CC) infusions per bleed .
Response of bleed to moroctocog alfa (AF -CC) treatment (4 -point scale of 
assessment, see Section 18.1.3).
Time interval between bleed onset and prior moroctocog alfa (AF -CC) prophy laxis 
dose.
Incidence of proph ylaxis regimen escalation.
Incidence of LETE (see Section 18.2).
Consumption of moroctocog a
lfa (AF- CC).
Compliance with assigned prophy laxis regimen.
Note: All subjective assessments will be provided by [CONTACT_232289].
22.3. Pharmacokinetic Variables
Primary  variables:
Terminal phase half -life (t ½).
Clearance (CL) .
Incremental recovery .
Secondary  PK variables:
maximum concentration (FVIII:C at 0.5 hours after study  drug infusion [C 0.5 hr]).
area under the curve to infinity  (AUC).
area under the curve to last measurable concentration (AUC t).

Moroctocog alfa (AF -CC) 
3082B2 -313-WW –(B1831001) 
Final Amendm ent 
10,02 October 2015
Page 62steady -state volume of distribution (V ss).
mean residence time (MRT) .
22.4. Subject Populations in the Analysis of Study Variables
22.4.1. Safety Variables
The safet y analyses will be performed on the intent -to-treat (ITT) population.  This 
population includes all subjects who sign the informed consent/assent form.   Screen failures 
will not be included in the ITT population .
Analy sis of the incidence of confirmed FVIII inhibitor development will be performed on the 
modified intent
-to-treat (mI TT) population.  The mI TT population consists of the subset of 
ITT subject s who received at least one dose of study  drug. 
22.4.2. Efficacy Variables
The efficacy anal yses will be performed on the ITT population.  This population includes all 
subjects who sign the informed consent/assent form.  Screen failures will not be included in 
the ITT population.  If a subject develops a confirmed FVIII inhibitor, his data will be 
included up to the time an inhibitor is determined to be present.
Efficacy  anal yses will also be performed on per- protocol populations.  The statistical analy sis 
plan wi ll define per -protocol populations.
22.4.3. Pharmacokinetic Variables
All FVIII:C data will be reported.  Individual pharmacokinetic anal ysis will be performed on 
all subjects for whom an adequate pharmacokinetic profile has been obtained.
22.5. Analysis of Study Variab les 
22.5.1. General
A discussion of the statistical methods by  [CONTACT_232290] ( see section 22.5.3).  In addition, continuous variables for PK, efficacy , and 
safet y analyses will be summariz ed by  [CONTACT_9086].  Categorical variables will be 
presented in frequency  tables, with counts and percent ages provided for each category .  
Missing data will be reported as such and no imputation will be made.  Additional details of 
the study  anal yses will be provided in the statistical anal ysis plan.
22.5.2. Safety Variables
The number (%) of subjects experiencing an y AE will be reported.  AEs will be 
summarized by  [CONTACT_232291] (AF -CC).  The incidence of AEs by  [CONTACT_11370] y and the incidence of 
AEs by  [CONTACT_232292] (AF- CC) will also be summarized.
The number (%) of subjects who develop a confirmed FVIII inhibitor will be 
reported, and categorized by  [CONTACT_232293] (ie, hi gh or low).

Moroctocog alfa (AF -CC) 
3082B2 -313-WW –(B1831001) 
Final Amendm ent 
10,02 October 2015
Page 6322.5.3. Efficacy Variables
The annualized bleed rate (ABR) is the primary endpoint for testing the primary  objective of 
the study , as well as for testing one of the secondary  objectives of the study.  ABRs will 
reflect the incidence of bleeds treated w ith FVIII replacement therap y.  To avoid potential 
bias related to prior treatment, the first month of each protocol -defined prophy laxis treatment 
will serve as a washout period; ABR analy ses will be performed with and without data from 
this washout period . 
For the primary  objective of demonstrating that moroctocog alfa (AF -CC) 
prophy laxis reduces the ABR relative to on- demand therap y, the null h ypothesis is 
that prophy lactic treatment does not reduce the ABR relative to on -demand treatment.  
The alternative hy pothesis is that prophy lactic therapy  does reduce the ABR.
To test the hy pothesis, an anal ysis of variance (ANOVA) will be conducted to 
compare the mean ABR between subjects in on- demand (segment 1) and prophylaxis 
(segment 2) treatment regimens.  Onl y subjects who practice on -demand therap y with 
moroctocog alfa (AF -CC) during segment 1, before starting the protocol- defined 
moroctocog alfa (AF -CC) prophy laxis in segment 2, will be included in this anal ysis.  
The ANOVA will include factors for treatment regimen (study  segment 1 or 2).  The 
model will also include a blocking factor for subjects to ensure that the comparison of 
ABRs from each treatment regimen is performed on a within subject basis.  The 
p-value for treatment regimen calculated in ABR of t he ITT population will be used 
to test the null hy
pothesis; a p -value less than 0.05 will be considered significant.
For the secondary  objective of assessing the effect of a high -versus low -frequency  
dosing schedule on the efficacy  of moroctocog alfa (AF -CC) prophy laxis, the null 
hypothesis is that there is a difference in mean ABR between the two prophy laxis 
regimens.  The alternative hy pothesis is that the two prophy laxis regimens are similar 
enough to be considered clinically  equivalent.  To test this hypothesis, the two
protocol -defined proph ylaxis regimens (a high -and a low -frequency  dosing regimen) 
will be assessed in a crossover design.  Onl y subjects who practice protocol -defined 
prophy laxis regimens in segment 1 and 2, respectively : the low -followed by  [CONTACT_232294]-frequency  dosing regimen (AB), or the high- followed b y the low- frequency  
dosing regimen (BA) will be included in this analysis.
The90% 2 -sided confidence interval (CI) for the mean difference in ABRs for 
the 2 proph ylaxis regimens for IT T subjects will be constructed using the t 
distribution with n -1 degrees of freedom (n equals the number of subjects) to 
assess the equivalence of these 2 regimens.  Equivalence will be demonstrated 
if the limits of the 90% CI fall wholly  within the interv al of ( –4, 4) bleeds per 
year.
ABR will also be presented as descriptive statistics (n, mean, SD, median, minimum, 
and maximum).  ABRs will be summarized by  [CONTACT_232295] t ype (ie, spontaneous or 
traumatic), b y bleed location (eg, joint, soft tissue/muscle), and b y treatment period
(ie, on- demand therap y or proph ylaxis). 

Moroctocog alfa (AF -CC) 
3082B2 -313-WW –(B1831001) 
Final Amendm ent 
10,02 October 2015
Page 64Additional efficacy  variables:
Number of stud y drug infusions used to treat a bleed will be summarized by [CONTACT_232296] (IU/kg) administered at the first infusion.
The 4 -point response (efficacy  rating) for study  drug -treated bleeds will be 
summarized, and an y successive ratings of “ No Response ” will also be reported.  The 
response to the first study  drug infusion to treat a bleed will be tabulated by  [CONTACT_232297].  First infusion responses will also be 
summarized by  [CONTACT_232298] (IU/kg).
The time between onset of a bleed and prior moroctocog alfa (AF- CC) routine 
prophy laxis infusion will be summarized by  [CONTACT_232299]: 24, > 24-48, 
>
48-72, and >72 hours.
The number (%) of subjects requiring proph ylaxis regimen escalation during 
protocol -defined proph ylaxis will be provided, and will be reported for each 
protocol -defined regimen.
The number (%) of subjects reporting LETE (see Section 18.2) will be provided.
For consumption of moroctocog alfa (AF
-CC) per bleed, first infusion (IU/kg) and 
total dose (IU/kg) administered for the bleed will be summarized by  [CONTACT_232300] 
(joint, soft tissue/muscle, multiple sites, and other).  For consumption of moroctocog 
alfa (AF -CC) over time, the number of infusions, exposure day s (ED), and dose 
(IU/kg and IU) per infusion will be summarized by [CONTACT_232301] (ie, on -demand 
or proph ylaxis).  Descriptive statistics (n, mean, SD, median, minimum, and 
maximum) will be provided.
Descriptive statistics will be provided to summarize subject compliance to their 
assigned proph ylaxis regimen (dose [IU/kg] and dose freq uency  [number of infusions 
per week]).  The number of infusions and the number of days (and weeks) on each 
assigned proph ylaxis regimen will be presented for each subject.
22.5.4. Pharmacokinetic Variables
All PK variables (see Se ction 19.1, 22.3) will be summarized by  [CONTACT_9086] 
(number [n], mean, median, standard deviation [SD], standard error [SE], minimum and 
maximum, coefficient of variance [CV %], geometric mean, and 95% confidence intervals 
[CI]).
Graphic exploration of potential relationships between age, weight, bod y
-surface area and 
body  mass index and CL , Vss, t ½and incremental recovery  will be performed.
22.6. Interim Analysis and Report
Anindependent E -DMC will periodically  review data from the study  to ensure subject safet y, 
with review intervals of approximately  every  6 months.  See Section 17 formore information 
regarding the E -DMC.

Moroctocog alfa (AF -CC) 
3082B2 -313-WW –(B1831001) 
Final Amendm ent 
10,02 October 2015
Page 65Prior to study  completion, selected (safet y, efficacy and/or PK ) data from this study  may  be 
summarized and reported to regulatory  authorities to support regulatory  submissions or 
requests. The anal yses for these summaries would be based on des criptive statistics. 
Per discussions with the FDA, a final report for the OD cohort will be submitted comparing 
prophy laxis efficacy  and safet y versus on -demand therap y according to section 3.[ADDRESS_280305] and second segments.   Data from a previous ReFacto PUP study  (Wy eth 
protocol 3082A1
-301- WW) guided assumptions for the sample size estimates for objectives 
of this study .  Additional information regarding each of these sample size estimates is 
provided below.
In the completed ReFacto 3082A1 -
301-WW PUP study , a reduction in the ABR was 
observed for subjects during their periods of prophylaxis ( 2 infusions per week) compared 
to their periods of on -demand therap y (reduction of 5.7 6.9 bleeds per year, [11.85 to 
6.15 bleeds per year], ABR decrease of 48%, N=39).  Based upon this experience, a more 
conservative decrease in ABR of 40% (corresponding to a mean change of 4.75 bleeds per 
year) and a standard deviation of 7 were selected for use in power calculations for the 
comparison of ABRs in the on -demand versus prophy laxis setting for this study  (see 
Section
22.4.2 for description of statistical analy sis).  A sample size of 18 OD subjects who 
practice on -demand therapy  in segment 1, followed by  [CONTACT_232302] 2, provide s
80% power to detect such a difference using a 2 -sided alpha level of 0.05.  Due to an 
expected attrition rate of up to 25%, approximately  24 OD subjects, who practice on -demand 
therap y during segment 1, were planned to be enrolled to ensure that 18 are evaluable for the 
comparison of ABRs in the on -demand versus prophy laxis setting.   Because enrollment into 
the OD cohort has been closed, all available data will be anal yzed.
For 
the RP cohort, the comparison of high -versus low -frequency  proph ylaxis dosing 
schedules, a subset anal ysis of data from the completed ReFacto PUP study (Wy eth protocol 
3082A1-301- WW) r evealed an ABR of 5.7 5.2 (N=26) in patients receiving a 
high-frequency  proph ylaxis regimen (3 infusions per week) compared to an ABR of 
7.14.1(N=13) in patients receiving a lower -frequency  proph ylaxis regimen (2 infusions per 
week).  However, the trea tment assignment was not randomized and prophy laxis regimens 
were not controlled in that study.  To avoid selection bias and inter -patient variability  
affecting outcome, twoprotocol -defined proph ylaxis regimens (a high-and a low -frequency  
dosing regimen) will be assessed in a crossover design. Assuming an intraclass correlation 
of 30% and a standard deviation of [ADDRESS_280306] deviation of 5 bleeds per y ear was used for sample size 
ca
lculations for the comparison between the twoprotocol -defined proph ylaxis regimens 
(Aand B).  Given this, 36 RP subjects are needed to provide 80% power to demonstrate 
equivalence of the tworegimens (see Section 22.5.3 for description of statistical anal ysis).  

Moroctocog alfa (AF -CC) 
3082B2 -313-WW –(B1831001) 
Final Amendm ent 
10,02 October 2015
Page 66Allowing for an attrition rate of 25%, approximately  [ADDRESS_280307] udy, a difference of 
means of 1.3 bleeds per year between the twoprotocol- defined proph ylaxisregimens (A and 
B) with a corresponding standard deviation of the difference of 6.5 was obtained requiring 
38 subjects to provide 80% power to demonstrate equiva lence of the two regimens.  
Allowing for an attrition rate of 30%, approximately  56
RP subjects need to be enrolled.  The 
two prophy laxis regimens will be considered equivalent if the limits of the 2 -sided 90% 
confidence interval for the difference in obse rved mean ABRs fall wholly  within the interval 
defined b y fewer than [ADDRESS_280308] who discontinues 
or is withdrawn (including screen failures), who reenrolls at a later time must be assigned a 
new subject number.  A number must never be reassigned or reused for any  reason.  The 
investigator must maintain a log (see Section 12) linking the subject number to the subject’s 
name.  The investigator must follow all applicable privacy  laws in order to protect a subject’s 
privacy  and confidentiality .  Information that could identify  a subject will be masked on 
material received b y the Sponsor.
24.TEST ARTICLE ACCOUNT ABILITY, RECONCILIAT ION, AND RETURN
The investigator must maintain a complete and current dispensing and inventory  record that 
has been supplied b y the Sponsor.  All used and unused vials of study drug, and unused 
diluent must be returned by  [CONTACT_423]/caregiver to the study  site in the original containers.  
See Section
16.7 for further details.
25.RANDOMIZATION
Randomization for assignment of a treatment regimen(s) to be followed during this study  will 
be performed during the screening period (interval of up t o approximatel y 35 day s, starting 
from the signing of the informed consent/assent and extending up to visit 2) after 
confirmation of stud y eligibility , and as specified in the Study  Reference Manual.  All
subjects will practice prophy laxis for both segment s of the study , will be randomly  assigned 
in a 1:1 ratio to 1 of 2 treatment sequences (AB or BA) defining the proph ylaxis regimens to 
be practiced during segments 1 and 2, respectivel y: the low -followed b y the high- frequency  
dosing regimen (AB), or the h igh-followed b y the low -frequency  dosing regimen (BA).  
Randomization will be stratified b y hemophilia A severit y: FVIII activity  <1% or 1- 2% 
(central laboratory  screening result).  Allocation of subjects to treatment assignments will be 
performed using a n interactive voice or web -based response s ystem.  Dropouts after 
randomization will not be replaced.

Moroctocog alfa (AF -CC) 
3082B2 -313-WW –(B1831001) 
Final Amendm ent 
10,02 October 2015
Page 6726.ADVERSE EVENT REPORT ING
For safet y information on moroctocog alfa (AF -CC), refer to the most recent version of the 
Single Reference Safety  Document, which for this study  is the investigator’s brochure.
26.1. Adverse Events
All observed or volunteered adverse events (AEs) regardless of treatment group or suspected 
causal relationship to the investigational product(s) will be reported as described in the 
following sections. 
For all AEs, the investigator must pursue and obtain information adequate both to determine 
the outcome of the AE and to assess whether it meets the criteria for classification as a 
serious adverse event (SAE) requiring immediate notification to [COMPANY_007] or its designated 
representative.  For all AEs, sufficient information should be obtained by  [CONTACT_8889].  The investigator is required to assess causality .  
Follow -up by  [CONTACT_232303] a level acceptable to the investigator, and [COMPANY_007] concurs with that assessment.
As part of ongoing safet y reviews conducted b y the Sponsor, an y non -serious adverse event 
that is determined b y the Spons or to be serious will be reported b y the Sponsor as an SAE.  
To assist in the determination of case seriousness further information may  be requested from 
the investigator to provide clarit y and understanding of the event in the context of the clinical 
study.
26.2. Reporting Period
For SAEs, and confirmed FVIII inhibitors, the active reporting period to [COMPANY_007] or its 
designated representative begins from the time that the subject provides informed consent, 
which is obtained prior to the subject’s participation in the study , ie, prior to undergoing an y 
study -related procedure and/or receiving investigational product, through and including 
28calendar day s after the last administration of the investigational product.  SAEs occurring 
to a subject after the active repo rting period has ended should be reported to the sponsor if 
the investigator becomes aware of them; at a minimum, all SAEs that the investigator 
believes have at least a reasonable possibility  of being related to investigational product are 
to be reported to the sponsor.
AEs (serious and non -serious) should be recorded on the case report form (CRF) from the 
time the subject has taken at least [ADDRESS_280309]’s last 
visit.
26.3. Definition of an Adverse Event
An AE is an y unto ward medical occurrence in a clinical investigation subject administered a 
product or medical device; the event need not necessarily  have a causal relationship with the 
treatment or usage.  Examples of AEs include but are not limited to:  
Abnormal test fi ndings;

Moroctocog alfa (AF -CC) 
3082B2 -313-WW –(B1831001) 
Final Amendm ent 
10,02 October 2015
Page 68Clinically  significant symptoms and signs;
Changes in physical examination findings;
Hypersensitivity ;
Progression/worsening of underl ying disease.
Drug abuse;
Drug dependency ;
Additionally , they  may  include the signs or s ymptoms resulting from:
Drug overdose;
Drug withdrawal;
Drug misuse; 
Drug interactions;
Extravasation;
Exposure during pregnancy (EDP);
Exposure via breast feeding ;
Medication Error ;
Occupational exposure .
26.3.1. Hemophilia Events
Hemophilia Events are certain AEs that are likely to occu r due to the subject’s hemophilia.  
For example, pain, swelling, or decreased range of motion due to a bleed may  be an expected 
consequence of hemophilia (per Section 18.1, the bleeding epi[INVESTIGATOR_28948] e itself is not reported as an 
AE, unless the bleeding epi[INVESTIGATOR_232230] a Serious Adverse Event).  
Investigators will be asked to determine if an AE is expected because of the subject’s 
hemophilia.  Bleeding or bruising, not due to the subjec t’s hemophilia, will be recorded as an 
AE, and not a hemophilia event.  Hemophilia events that require hospi[INVESTIGATOR_232231]. 
26.4. Abnormal Test Findings
The criteria for determining whether an abnormal objective
test finding should be reported as 
an AE are as follows: 
Test result is associated with accompan ying symptoms, and/or

Moroctocog alfa (AF -CC) 
3082B2 -313-WW –(B1831001) 
Final Amendm ent 
10,02 October 2015
Page 69Test result requires additional diagnostic testing or medical/surgical intervention, 
and/or
Test result leads to a change in study  dosin g (outside of protocol- stipulated dose 
adjustments) or discontinuation from the study , significant additional concomitant 
drug treatment, or other therap y, and/or
Test result is considered to be an adverse event b y the investigator or Sponsor.
Merel y repea ting an abnormal test, in the absence of any  of the above conditions, does not 
constitute an adverse event.  Any  abnormal test result that is determined to be an error does 
not require reporting as an adverse event.
26.5. Serious Adverse Events
A serious adverse event is any  untoward medical occurrence at any  dose that:
Results in death;
Is life -threatening (immediate risk of death);
Requires inpatient hospi[INVESTIGATOR_1081];
Results in persistent or significant disability /incapacity  (substantial disruption of the 
ability  to conduct normal life functions);
Results in congenital anomaly /birth defect.
Lack of efficacy  should be reported as an AE when it is associated with an SAE.
Medical and scientific judgment is exercised in de termining whether an event is an important 
medical event.  An important medical event may  not be immediately  life-threatening and/or 
result in death or hospi[INVESTIGATOR_059].  However, if it is determined that the event may  jeopardize 
the subject or may  require intervention to prevent one of the other adverse event outcomes, 
the important medical event should be reported as serious.
Examples of such events are intensive treatment in an emergency  room or at home for 
allergic bronchospasm; blood dy scrasias or convulsions that do not result in hospi[INVESTIGATOR_059]; 
or development of drug dependency  or drug abuse.
The following event must be considered medically  important and has the same reporting 
requirements as SAEs:
Confirmed FVIII inhibitor development.  For the purp oses of this study , a confirmed 
FVIII inhibitor is a Nijmegen assay  result of0.6 BU/mL  at the central laboratory .

Moroctocog alfa (AF -CC) 
3082B2 -313-WW –(B1831001) 
Final Amendm ent 
10,02 October 2015
Page 7026.5.1. Protocol -Specified Serious Adverse Events 
There are no protocol -specified SAEs in this study .  All SAEs will be reported by  [CONTACT_192682] r as described in previous sections, and will be handled as SAEs in the safet y 
database (see Section 26.13.1 Serious Adverse Event Reporting Requirements). 
26.5.2. Potential Cases of Drug- Induced Liv er Injury (Potential Hy’s Law Cases)
Abnormal values in aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) 
levels concurrent with abnormal elevations in total bilirubin level that meet the criteria 
outlined below in the absence of other causes of liver injury  are considered potential cases of 
drug-induced liver injury (potential Hy ’s Law cases) and should alway s be considered 
important medical events. 
The threshold of laboratory  abnormalities for a potential case of drug- induced liver i njury  
depends on the subject’s individual baseline values and underl ying conditions.   Subjects who 
present with the following laboratory  abnormalities should be evaluated further to 
definitively  determine the etiology  of the abnormal laboratory
 values:
Subjects with AST or ALT and total bilirubin baseline values within the normal range 
who subsequently  present with AST or AL T 3 times the upper limit of normal 
(xULN) concurrent with a total bilirubin value[ADDRESS_280310] with no evidence of 
hemoly sis and an alka line phosphatase [ADDRESS_280311] or not available.
For subjects with preexisting AL T OR AST OR total bilirubin values above the 
upper limit of normal, the following threshold values should be used in the definition 
mentioned above:
For subjects with pre -existing AST or AL T baseline values above the normal 
range: AST or ALT 
2times the baseline values and  [ADDRESS_280312], or [ADDRESS_280313] 
(whichever is smaller).
Concurrent with
For subjects with pre -existing values of total bilirubin above the normal range: 
Total bilirubin level increased from baseline by [CONTACT_8895] [ADDRESS_280314] or
if the value reaches 3x ULN (whichever is smaller).
The subject should return to the investigational site and be evaluated as soon as possible, 
preferabl y within [ADDRESS_280315] bilirubin, gamma- glutamy l 
transferase, prothrombin time (PT)/international normalized ratio ( INR) and alkaline 
phosphatase.  A detailed history , including relevant information, such as review of ethanol, 
acetaminophen, recreational drug and supplemen t consumption, family  history , occupational 
exposure, sexual history , travel history , history  of contact [CONTACT_4490] a jaundiced person , surgery , 

Moroctocog alfa (AF -CC) 
3082B2 -313-WW –(B1831001) 
Final Amendm ent 
10,02 October 2015
Page 71blood transfusion, history of liver or allergic disease, and work exposure, should be collected.  
Further testing for acute hepatitis A, B, or C infection and liver imaging (eg, biliary  tract) 
may be warranted.   All cases confirmed on repeat testing as meeting the laboratory  criteria 
defined above, with no other cause for LFT abnormalities identified at the time should b e 
considered potential Hy ’s Law cases irrespective of availability  of all the results of the 
investigations performed to determine etiology  of the abnormal LFTs.  Such potential Hy ’s 
Law cases should be reported as SAEs.
26.6. Hospi[INVESTIGATOR_47575] y initial admission (even less than 24 hours) in a hospi[INVESTIGATOR_8843].  Admission also 
includes transfer within the hospi[INVESTIGATOR_4591]/intensive care unit (eg, from the psy chiatric 
wing to a medical floor, medical floor to a coronary  care unit, or neurological floor to a 
tuberculosis unit).  An emergency  room visit does not necessarily constitute a hospi[INVESTIGATOR_059]; 
however, the event leading to the emergency  room visit shoul d be assessed for medical 
importance.
Hospi[INVESTIGATOR_4592]:
Rehabilitation facilities;
Hospi[INVESTIGATOR_4593];
Respi[INVESTIGATOR_4594] (eg, caregiver relief);
Skilled nursing facilities;
Nursing homes;
Same day  surgeries (as outpatient/same day /ambulatory  procedures).
Hospi[INVESTIGATOR_4595] a precipi[INVESTIGATOR_2505], clinical 
adverse event is not in itself a serious adverse event.  Examples include: 
Admission for treatment of a preexisting condition not associ ated with the 
development of a new adverse event or with a worsening of the preexisting condition 
(eg, for work -up of persistent pre -treatment lab abnormality );
Social admission (eg, subject has no place to sleep);
Administrative admission (eg, for yearly physical exam);
Protocol -specified admission during a study  (eg, for a procedure required by  [CONTACT_8896]);

Moroctocog alfa (AF -CC) 
3082B2 -313-WW –(B1831001) 
Final Amendm ent 
10,02 October 2015
Page 72Optional admission not associated with a precipi[INVESTIGATOR_10244] (eg, for 
elective cosmetic surgery);
Hospi[INVESTIGATOR_232232] a medical AE;
Pre-planned treatments or surgical procedures .  These should be noted in the baseline 
documentation for the entire protocol and/or for the individual subject.
Diagnostic and therapeutic non- invasive and invasive procedures, such as surgery , should not 
be reported as adverse events.  However, the medical condition for which the procedure was 
performed should be reported if it meets the definition of an adverse event.  For example, an 
acute appendicitis that begins during the advers e event reporting period should be reported as 
the adverse event, and the resulting appendectomy  should be recorded as treatment of the 
adverse event.
26.7. Severity Assessment
If required on the adverse event CRFs , the investigator will use the adjectives MILD,
MODERATE, or SEVERE to describe the maximum intensity  of the adverse event.  For 
purposes of consistency , these intensity  grades are defined as follows:
MILD Does not interfere with subject's usual function.
MODERATE Interferes to some extent with subje ct's usual function.
SEVERE Interferes significantl y with subject's usual function.
Note the distinction between the severit y and the seriousness of an adverse event.  A severe 
event is not necessarily  a serious event.  For example, a headache may be severe (interferes 
significantly  with subject's usual function) but would not be classified as serious unless it met 
one of the criteria for serious adverse events, listed above.
26.8. Causality Assessment
The investigator’s assessment of causalit y must be provided for all adverse events (serious 
and non- serious); the investigator must record the causal relationship in the CRF, as 
appropriate, and report such an assessment in accordance with the SAE reporting 
requirements if applicable.  An investigator’s causality  assessment is the determination of 
whether there exists a reasonable possibility  that the investigational product caused or 
contributed to an adverse event; generally  the facts (evidence) or arguments to suggest a 
causal relationship should be provided.  I f the investigator does not know whether or not the 
investigational product caused the event, then the event will be handled as “related to 
investigational product” for reporting purposes, as defined b y the Sponsor (see the 
Section
26.13 on Reporting Requirements).  If the investigator's causalit y assessment is 
“unknown but not related to investigational product” , this should be clearl y documented on 
study  records. 
In addition, if the investig ator determines a serious adverse event is associated with study  
procedures, the investigator must record this causal relationship in the source documents and 

Moroctocog alfa (AF -CC) 
3082B2 -313-WW –(B1831001) 
Final Amendm ent 
10,02 October 2015
Page 73CRF, as appropriate, and report such an assessment in accordance with the serious adverse 
event r eporting requirements, if applicable.
26.9. Exposure During Pregnancy
For both unapproved/ unlicensed products and for marketed products, an exposure during 
pregnancy  (also referred to as exposure in-utero [EIU]) occurs if:
1.A female becomes, or is found to be, pr egnant either while receiving or having been 
exposed (eg, because of treatment or environmental exposure) to the investigational 
product; or the female becomes or is found to be pregnant after discontinuing and/or 
being exposed to the investigational produ ct; 
2.An example of environmental exposure would be a case involving direct contact [CONTACT_4490] 
a [COMPANY_007] product in a pregnant woman (eg, a nurse reports that she is pregnant and has 
been exposed to chemotherapeutic products).
3.A male has been exposed (eg, due to t reatment or environmental exposure) to the 
investigational product prior to or around the time of conception or is exposed during 
his partner’s pregnancy .
If a stud y subject or study subject’s partner becomes or is found to be pregnant during the 
study  subject’s treatment with the investigational product, the investigator must submit this 
information to the [COMPANY_007] drug safet y unit on an SAE report form and an EDP supplemental 
form, regardless of whether an SAE has occurred .  In addition, the investigator must submit 
information regarding environmental exposure to a [COMPANY_007] product in a pregnant woman (eg, a 
subject reports that she is pregnant and has been exposed to a cy totoxic product by  [CONTACT_8897][INVESTIGATOR_4598]) using the EDP supplemental form.  This must be done irrespective of whether an 
AE has occurred and within 24 hours of awareness of the exposure.  The information 
submitted should include the anticipated date of delivery  (see below for information related 
to termination of pregnancy ).
Follow -up is conducted to obtain general information on the pregnancy and its outcome for 
all EDPreports with an unknown outcome.  The investigator will follow the pregnancy  until 
completion or (pregnancy  termination )and notify [COMPANY_007] of the outcome as a follow up to the
initial E DPForm.  I n the case of a live birth, the structural integrit y of the neonate can be 
assessed at the time of birth.  I n the event of a termination, the reason(s) for termination 
should be specified and, if clinically  possible, the structural int egrity of the terminated fetus 
should be assessed by [CONTACT_4692] (unless pre -procedure test findings are 
conclusive for a congenital anomal y and the findings are reported).
If the outcome of the pregnancy  meets the criteria for an SAE (ie, ecto pic pregnancy , 
spontaneous abortion, intrauterine fetal demise, neonatal death, or congenital anomal y [in a 
live born baby, a terminated fetus, an intrauterine fetal demise, or neonatal death]), the 
investigator should follow the procedures for reporting serious adverse events.

Moroctocog alfa (AF -CC) 
3082B2 -313-WW –(B1831001) 
Final Amendm ent 
10,02 October 2015
Page 74Additional information about pregnancy  outcomes that are reported as serious adverse events 
follows: 
“Spontaneous abortion” includes miscarriage and missed abortion;
Neonatal deaths that occur within [ADDRESS_280316].
Additional information regarding the exposure during pregnancy  may  be requested by  [CONTACT_1275].  Further follow -up of birth outcomes will be handled on a case- by-case basis 
(eg, follow -up on preterm infants to identify  developmental d elays).  In the case of paternal 
exposure, the investigator will provide the study  subject with the Pregnant Partner Release of 
Information Form to deliver to his partner.  The Investigator must document on the Form that 
the subject was given this letter to provide to his partner.
26.10. Occupational Exposure
An occupational exposure occurs when, during the performance of job duties, a person 
(whether a healthcare professional or otherwise) gets in unplanned direct contact [CONTACT_8898], which may  or may  not le ad to the occurrence of an AE.
An occupational exposure is reported to the drug safet y unit within 24 hours of the 
investigator’s awareness, using the SAE report form, regardless of whether there is an 
associated AE/SAE.  Since the information does not per tain to a subject enrolled in the study , 
the information is not reported on a CRF; however, a copy  of the completed SAE report form 
is maintained in the investigator site file.
26.11. Withdrawal Due to Adverse Events (See Also Section 
27-Subject 
Discontinuation or Withdrawal)
Withdrawal due to AEs should be distinguished from withdrawal due to other causes, 
according to the definition of AE noted earlier, and recorded on the appropriate AE CRF 
page.
When a subject withdraws because of a serious adverse event, the serious adverse event must 
be reported in accordance with the reporting requirements defined below.
26.12. Eliciting Adverse Event Information
The investigator is to report all directly  observed ad verse events and all adverse events 
spontaneously  reported by  [CONTACT_232304].  In addition, each study  subject will be 
questioned about adverse events.

Moroctocog alfa (AF -CC) 
3082B2 -313-WW –(B1831001) 
Final Amendm ent 
10,[ADDRESS_280317] be made immediatel y, irrespective of the 
extent of available AEinformation.  This timeframe also applies to additiona l new 
information (follow -up) on previously  forwarded serious adverse event reports as well as to 
the initial and follow -up reporting of EDP, exposure via breastfeeding and occupational 
exposure cases. 
In the rare event that the investigator does not beco me aware of the occurrence of a serious 
adverse event immediately  (eg, if an outpatient study  subject initially  seeks treatment 
elsewhere), the investigator is to report the event within 24 hours after learning of it and 
document the time of his/her first awareness of the adverse event.
For all SAEs , the investigator is obligated to pursue and provide information to [COMPANY_007] in 
accordance with the timeframes for reporting specified above.  In addition, an investigator 
may be requested by  [CONTACT_232305] -up information in an 
expedited fashion.  This information collected for serious adverse events is more detailed 
than that captured on the AE CRF .  In general, this will include a description of the adverse 
event in sufficient detail to allow for a complete medical assessment of the case and 
independent determination of possible causalit y.  Information on other possible causes of the 
event, such as concomitant medications and vaccines and/or illnesses must be provided.  In 
the case of a subject death, a summary  of available autopsy  findings must be submitted as 
soon as possible to [COMPANY_007] or its designated representative. 
26.13.2. Non-Serious Adverse Event Reporting Requirements
All adverse events will be reported on the adverse event page(s) of the CRF.  I t should be 
noted that the form for collection of serious adverse event information is not the same as the 
AECRF.  Where the same data are collected, the forms must be completed in a consistent 
manner.  For example, the same adverse event term should be used on both forms.  AEs
should be reported using concise medical terminology  on the CRFs as well as on the form for 
collection of serious adverse event information.
26.13.3. Sponsor ’sReporting Requirements to Regulatory Authorities
Adverse event report ing, including suspected unexpected serious adverse reactions, will be 
carried out in accordance with applicable local regulations.
26.14. Medication Errors
Medication errors may  result, in this study , from the administration or consumption of the 
wrong product, by  [CONTACT_1148], at the wrong time, or at the wrong dosage strength.  

Moroctocog alfa (AF -CC) 
3082B2 -313-WW –(B1831001) 
Final Amendm ent 
10,02 October 2015
Page 76Such medication errors occurring to a study participant are to be captured on the medication 
error CRF, which is a specific version of the AE page, and on the SAE form when 
appropri ate.  In the event of medication dosing error, the sponsor should be notified 
immediately .
Medication errors are reportable irrespective of the presence of an associated AE/SAE, 
including:
Medication errors involving subject exposure to the investigational product .
Potential medication errors or uses outside of what is foreseen in the protocol that do 
or do not involve the participating subject.
Whether or not the medication error is accompanied by  [CONTACT_1149], as determined by  [CONTACT_1275], the medication e rror is captured on the medication error version of the AE page 
and, if applicable, an y associated AE(s) are captured on an AE CRF page. 
27.SUBJECT DISCONTINUAT ION OR WITHDRAWAL
Reasons wh y a subject may discontinue or be withdrawn from the study include, bu t are not 
limited to, AE, subject request, protocol violation, subject noncompliance, study  termination 
by [CONTACT_1034], and if the investigator believes it is not in the subject’s best interest to 
continue participating in the study .  Discontinued or withdrawn subjects will not be replaced.  
Subjects will be withdrawn from the stud y by [CONTACT_232306] .  This 
will occur even if the local labora tory results indicate the subject is eligible.  Subjects will be 
withdrawn from the study if a FVIII inhibitor, confirmed by  [CONTACT_2237] , develops 
during the study .  Except for screen failures, when a subject discontinues or is withdrawn, the 
investigator will directly  notify  the S ponsor and, when possible, will perform the procedures 
indicated for the Final Study  Visit and Final Study  Contact, see Section 15.1.11 and15.1.12.  
For subjects who are withdrawn due to confirmed FVIII inhibitor development, see 
Section
15.3.2 for procedures.
27.1. Reporting of Safety I ssue and Serious Breaches of the Protocol or ICH GCP
In the event of an y prohibition or restriction imposed (ie, clinical hold) b y an applicable 
Competent Authority  in any  area of the World, or if the investigator is aware of any  new 
information which might influence the evaluation of the b enefits and risks of the 
investigational product, [COMPANY_007] should be informed immediately. 
In addition, the investigator will inform [COMPANY_007] immediately  of any  urgent safet y measures 
taken b y the investigator to protect the study subjects against an y immedia te hazard, and of 
any serious breaches of this protocol or of International Conference on Harmonisation ( ICH )
Good Clinical Practice ( GCP )that the investigator becomes aware of.

Moroctocog alfa (AF -CC) 
3082B2 -313-WW –(B1831001) 
Final Amendm ent 
10,[ADDRESS_280318] ETION
The Sponsor may  suspend or term inate the stud y or part of the stud y at any time for an y 
reason.
If the investigator suspends or terminates the study , the investigator will promptly  inform the 
Sponsor and the IRB/IEC and provide them with a detailed written explanation.  The 
investigator will also return all test article, test article containers, and other study  materials to 
the S ponsor.  Upon study completion, the investigator will provide the Sponsor, I RB/IEC, 
and regulatory  agency  with final reports and summaries as required by  [CONTACT_19124].  For 
investigational new drug (IND) studies, the investigator must submit a written report to the 
Sponsor and the I RB/IEC within [ADDRESS_280319]/Ethics Committee
It is the responsibility  of the investigator to have prospective approval of the study  protocol, 
protocol amendments, informed consent/assent documents, and other relevant documents, 
eg,recruitment advertisements, if applicable, from the I RB/ethics committee ( EC)
. All 
correspondence with the IRB/EC should be retained in the investigator file.  Copi[INVESTIGATOR_54603]/EC approvals should be forwarded to [COMPANY_007].
The only  circumstance in which an amendment may  be initiated prior to IRB/EC approval is 
where the change is necessa ry to eliminate apparent immediate hazards to the subjects.  In 
that event, the investigator must notify  the IRB/EC and [COMPANY_007] in writing immediately  after 
the implementation.
29.2. Ethical Conduct of the Study
The study  will be conducted in accordance with lega l and regulatory  requirements, as well as 
the general principles set forth in the International Ethical Guidelines for Biomedical 
Research Involving Human Subjects (Council for International Organizations of Medical 
Sciences 2002), Guidelines for GCP (ICH 1996), and the Declaration of Helsinki (World 
Medical Association 1996 & 2008).
In addition, the study  will be conducted in accordance with the protocol, the I CH guideline 
on GCP, and applicable local regulatory  requirements and laws.
29.3. Subject Information and Consent
All parties will ensure protection of subject personal data and will not include subject names 
or other identifiable data in any  reports, publications, or other disclosures, except where 
required b y law. 
When study  data are compi[INVESTIGATOR_232233], subject 
names, addresses, and other identifiable data will be replaced b y a numerical code based on a 
numbering sy stem provided by  [CONTACT_47617] -identify  study  subjects.   The study  site 
will maintain a con fidential list of subjects who participated in the study ,linking each 

Moroctocog alfa (AF -CC) 
3082B2 -313-WW –(B1831001) 
Final Amendm ent 
10,[ADDRESS_280320]’s numerical code to his actual identity .  In case of data transfer, [COMPANY_007] will maintain 
high standards of confidentiality  and protection of subject s’personal data consistent w ith 
applicable privacy  laws.
The informed consen t/assent documents must be in compliance with ICH GCP, local 
regulatory  requirements, and legal requirements, including applicable privacy  laws.
The informed consent /assent documents used during the informed consent process must be 
reviewed and approved by [CONTACT_456], approved by  [CONTACT_1201]/EC before use, and available for 
inspection.
The investigator must ensure that each study  subject or his legall y acceptable representative, 
or parent(s) or legal guardian i f a minor, is fully  informed about the nature and objectives of 
the study  and possible risks associated with participation. 
Whenever consent is obtained from a subject’s legally acceptable representative/parent(s) or 
legal guardian, the subject’s assent ( affirmative agreement) must subsequently  be obtained 
when the subject has the capacity  to provide assent, as determined by  [CONTACT_1201]/EC.  If the 
investigator determines that a subject’s decisional capacity  is so limited he/she cannot 
reasonabl y be consulted, then, as permitted b y the IRB/EC and consistent with local 
regulatory  and legal requirements, the subject’s assent may  be waived with source 
documentation of the reason assent was not obtained.  If the stud y subject does not provide 
hisorher own consent, the source documents must record wh y the subject did not provide 
consent (eg, minor, decisionally  impaired adult), how the investigator determined that the 
person signing the consent was the subject’s legally  acceptable representative, the consent 
signer ’s relationship to the study subject (eg, parent, spouse) ,and that the subject’s assent 
was obtained, or waived.  If assent is obtained verbally  it must be documented in the source 
documents.
If the stud y includes minor subjects who reach the age of major ity during the study , as 
recognized under local law, they  must re -consent as adults to remain in the study .  If the 
enrollment of ‘emancipated minors’ is permitted by [CONTACT_43038] y age criteria, the I RB/EC, and 
local law, they  must provide documentation of legal status to give consent without the 
permission of a parent or legal guardian.
The investigator, or a person designated b y the investigator, will obtain written informed 
consent from each subject's legall y acceptable representative, parent(s) or legal gua rdian and 
the subject’s assent, when applicable, before an y study -specific activity  is performed.  The 
investigator will retain the original of each subject's signed consent/assent document.
30. PROTOCOL AMENDMENTS
Any significant change in the study  requires a protocol amendment.  An investigator must 
not make an y changes to the study  without I RB/IEC and Sponsor approval except when 
necessary  to eliminate apparent immediate hazards to the subjects.  A protocol change 
intended to eliminate an apparent immediate hazard to subjects may  be implemented 
immediately , but the change must then be documented in an amendment, reported to the 

Moroctocog alfa (AF -CC) 
3082B2 -313-WW –(B1831001) 
Final Amendm ent 
10,02 October 2015
Page 79IRB/IEC within [ADDRESS_280321] be reviewed and approved by  [CONTACT_232307].
31.QUALITY CONTROL AND ASSURANCE
The Sponsor performs quality  control and assurance checks on all clinical studies that it 
sponsors.  Before enrolling any  subjects in this study , Sponsor pe rsonnel and the investigator 
review the protocol, the investigator’s brochure, the eCRFs and instructions for their 
completion, the procedure for obtaining informed consent/assent, and the procedure for 
reporting AEs and SAEs.  A qualified representative o f the 
Sponsor will monitor the conduct 
of the study  by [CONTACT_232308] b y contact[CONTACT_232309], fax, mail, 
or e-mail.  During these study  site visits, information recorded in the eCRFs is verified 
against source documents.
32.DIRECT ACCESS, DATA HANDLING, AND RECORD- KEEPI[INVESTIGATOR_1645]
32.1. Investigator
The investigator will permit study -related monitoring, audits, I RB/IEC review, and 
regulatory  inspections by [CONTACT_60282].
All information will be recorded o n source documents.  The subject’s medical record is 
considered to be the source document for the study  unless it is information collected 
specificall y for this study and recorded directl y in the subject’s Subject Diary or in eCRFs.  
All required data will be recorded in the eCRFs.  All eCRF data must be submitted to the 
Sponsor throughout and at the end of the stud y.  Remote data capture will be used to record 
and transmit data electronically  to the S ponsor.
Central laboratory  data will be transmitted dire ctly to the S ponsor.  There may  be no prior 
written or electronic record for these data.
If an investigator retires, relocates, or otherwise withdraws from conducting the study , the 
investigator must notify  the 
Sponsor to agree upon an acceptable storage s olution.  
Regulatory  agencies will be notified with the appropriate documentation.  An updated Form 
1572 will be filed with the S ponsor for an y changes in the study  personnel reported in the 
current Form 1572.
32.2. Sponsor
The eCRF data are stored in a database and processed electronically .  The Sponsor clinician 
reviews the data for safety information.  The data are reviewed for legibility, completeness, 
and logical consistency .  Automated validation programs identify  missing data, out -of-range 
data, and other data inconsistencies.  Requests for data clarification are forwarded to the 
investigative site for resolution.  By  [CONTACT_4907] , the investigator (and their 
designated staff) accepts responsibility  for resolving questions about study  data to the best of 
their ability .

Moroctocog alfa (AF -CC) 
3082B2 -313-WW –(B1831001) 
Final Amendm ent 
10,[ADDRESS_280322] to specific provisions in the Clinical Study  Agreement (CSA), if a subject 
is injured as a direct result of a test article, the Sponsor will pay  for reasonable and necessary  
medical treatment f or the injury , to the extent that such expenses are not covered by  [CONTACT_1560]’s medical insurance, a government program, or other responsible third part y.  If laws 
or regulations of the locality  in which the study  is taking place require additional pay ment of 
expenses, the S ponsor shall comply  with such laws or regulations.  Where applicable, the 
Sponsor has taken specific national insurance.
34.PRESTUDY DOCUMENTATI ON
The investigator must provide the Sponsor with the following documents BEFORE enrolling 
any subjects:
Completed and signed Form 1572.
All applicable country -specific regulatory  forms.
Current (within 2 y ears) signed and dated curricula vitae for the investigator, 
subinvestigators, and other individuals having significant investigator responsibili ty 
who are listed on the form 1572 or equivalent, or the clinical study  information form.
Copy  of the IRB/IECapproval letter for the protocol and informed consent.  All 
advertising, recruitment, and other written information provided to the subject must 
be approved b y the IRB/IEC.  Written assurance of continuing approval (at least 
annually ) as well as a copy  of the annual progress report submitted to the IRB/IEC 
must also be provided to the Sponsor.
Copy  of the IRB/IEC-approved informed consent document t o be used.
Where applicable, a list of the I RB/IEC members and their qualifications, and 
a
description of the committee’s working procedure.
Copy  of the protocol sign- off page signed b y the investigator.
Fully  executed CSA.
Where applicable, a financial di sclosure form.
A written document containing the name, location, certification number, and date of 
certification of the laboratory  to be used for laboratory  assay s and those of other 
facilities conducting tests.  This document should be returned along with the 
statement of investigator form (Form 1572).  The Sponsor must be notified if the 
laboratory is changed or if any  additional laboratory  is to be used.

Moroctocog alfa (AF -CC) 
3082B2 -313-WW –(B1831001) 
Final Amendm ent 
10,02 October 2015
Page 81List of normal laboratory values and units of measure for all laboratory  tests required 
by [CONTACT_60797].  This is required for each laboratory  to be used during the study .  The 
Sponsor must be notified if normal values or units of measurement change.
35. RECORDS RETENTION
The investigator shall retain and preserve 1 cop y of all data generated in the course of the 
study , specificall y including but not limited to those defined b y GCP as essential, for the 
longer of (i) 2years after the last marketing authorization for the study  drug has been 
approved or the Sponsor has discontinued its research with respect to such drug or (ii) such 
longer period as required by  [CONTACT_232310].  At the end of such 
period, the investigator shall notify  the S ponsor in writing of its intent to destroy  all such 
material.  The Sponsor shall have 30 days to r espond to the investigator’s notice, and the 
Sponsor shall have a further opportunity  to retain such materials at the Sponsor’s expense.
36.SAMPLE RETENTION
Samples may  be used for purposes related to this research, such as repeat testing is needed.  
The samples will be stored for up to [ADDRESS_280323].
38.PUBLICATION OF STUDY RESULTS
38.1. Communication of Results by [CONTACT_232311].clinicaltrials.gov (ClinicalTrials.gov), the European Clinical Trials 
Database (EudraCT), and/or www.pfizer.com , and other public registries in accordance with 
applicable local laws/regulations. 
In all cases, stud y results are reported b y [COMPANY_007] in an objective, accurate, balanced, and 
complete manner and are reported regardless of the outcome of the stud y or the country in 
which the study  was conducted.
www.clinicaltrials.gov
[COMPANY_007] posts clinical trial US Basic Results on www.clinicaltrials.gov for [COMPANY_007] -sponsored 
interventional studies conducted in patients that evaluate the safet y and/or efficacy of a [COMPANY_007] 
product, regardless of the geographical location in which the study is conducted.  US Basic 
Results are submitted for posting within 1 y ear of the primary  completion date for studies in 
adult populations or within 6 months of the primary completion date for studies in pediatric 
populations.

Moroctocog alfa (AF -CC) 
3082B2 -313-WW –(B1831001) 
Final Amendm ent 
10,[ADDRESS_280324] for all [COMPANY_007]- sponsored interventional studies that 
are in scope of EU requirements.  EU Basic Results are submitted for posting within 1 year 
of the primary  completion date for studies in adult populations or within 6 months of the 
primary  completion date for studies in pediatric populations.
www.pfizer.com
[COMPANY_007] posts Public Disclosure Sy nopses (clinical study  report sy nopses in which any  data 
that could be used to identify  individual patients has been removed) on ww w.pfizer.com for 
[COMPANY_007] -sponsored interventional studies at the same time the US Basic Results document is 
posted to www.clinicaltrials.gov.
38.2. Publications by [CONTACT_4716] [INVESTIGATOR_47582] y based on information collected or generated 
by [CONTACT_22660], whether or not the results are favorable to the [COMPANY_007] product.  
However, to ensure against inadvertent disclosure of confidential information or unprotected 
inventions, the investigator will provide [COMPANY_007] an opportunity  to review any  proposed 
publication or other type of disclosure of the results of the study (collectively, “Publication”) 
before it is submitted or otherwise disclose d.
The investigator will provide any  publication to [COMPANY_007] at least [ADDRESS_280325] to the 
other requirements of this section.
For all publications relating to the study , the institution will comply  with recognized ethical 
standards concerning publications and authorship, including Section II -“Ethical 

Moroctocog alfa (AF -CC) 
3082B2 -313-WW –(B1831001) 
Final Amendm ent 
10,[ADDRESS_280326] and Reporting of Research” of the Uniform Requirements for 
Manuscripts Submitted to Biomedical Journals, http://www.icmje.org/index.html#authorship, 
established by  [CONTACT_4717].
Publication of study  results is also provided for in the CSA between [COMPANY_007] and the 
institution.  I n this section entitled Publications by  [CONTACT_4718], the defined terms shall have 
the meanings given to them in the CSA.
If there is an y conflict between the CSA and a ny Attachments to it, the terms of the CSA 
control.  If there is an y conflict between this protocol and the CSA, this protocol will control 
as to any  issue regarding treatment of study  subjects, and the CSA will control as to all other 
issues.
39.REFERENCES
1. E aton DL, Wood WI , Eaton D, et al.  Construction and characterization of an active 
factor VIII variant lacking the central one -third of the molecule.  Biochemistry . 1986; 
25: 8343 8347.
2. Toole JJ, Pi[INVESTIGATOR_232234], Orr EC, Murtha P, Wasley  LC, Kaufman RJ.  A large region 
(~95 kDa) of human factor VIII is dispensable for in vitro procoagulant activity .  Proc 
Natl Acad Sci [LOCATION_003]. 1986; 83: 5939 -5942.
3. Wyeth investigator’s brochure: ReFacto (moroctocog alfa), [WAY -167652].
4. Sandberg H, Almstedt A, Brandt J, et al.  Struct ural and functional characterization of B 
domain deleted recombinant factor VIII.  Semin Hematol. 2001; 38([ADDRESS_280327] 4): [ADDRESS_280328]. 2002; 28(3): 
269-272.
6. Kelley  BD, Booth J, Tannatt M, et al.  Isolation of a peptide ligand for affinity  
purification of factor VIII using phage display .  J Chromatogr A. 2004; 1038: 121 -
130.
7. Kelley  BD, Tannatt M, Magnusson R, Hagelberg S, Booth J.  Development and 
validation of an affinity  chromatograph y step using a peptide ligand for cGMP 
production of factor VIII.   Biotechnol Bioeng. 2004; 87: 400-412.
8. [COMPANY_007] I nc. Periodic Safety  Update Report #[ADDRESS_280329]-2014.
9. Kessler CM, Gill JC, White GC, et al.  B -domain deleted recombinant factor VIII 
preparations are bioequivalent to a monoclonal antibody  purified plasma -derived factor 
VIII concentrate: a randomized, three- way crossover study .  Haemophilia. 2005; 11: 
84 91.

Moroctocog alfa (AF -CC) 
3082B2 -313-WW –(B1831001) 
Final Amendm ent 
10,02 October 2015
Page 8410. Aledort LM, Haschmey er RH, Pettersson H.  A longitudinal study  of orthopaedic 
outcomes for severe factor- VIII-deficient haemophiliacs.  J I ntern Med. 1994; 236: 
[ADDRESS_280330] of prophy lactic treatment on children with 
severe haemophilia.  Br J Haematol. 1996; 92: 973-978.
12. Manco -Johnson MJ, Abshire TC, Shapi[INVESTIGATOR_71324], et al.  Prophy laxis versus Epi[INVESTIGATOR_232235] s with Severe Hemophilia.  N Engl J Med. 
2007; 357;6: [ADDRESS_280331] T, Pettersson H.  Twenty -five years' experience of 
prophy lactic treatment in severe haemophilia A and B.  J I ntern Med. 1992; 232: 25-32.
14. Shapi[INVESTIGATOR_71324], Donfield SM, Ly nn HS, et al.  Defining the impact of hemophilia: the 
academic achievement in children with hemophilia study .  Pediatrics. 2001; 108: 
[ADDRESS_280332] J. WFH Guidelines for the
management of hemophilia. Available at: 
http://www.wfh.org/2/docs/Publications/Diagnosis_and_Treatment/Guidelines_Mng_H
emophilia.pdf
16. Berntorp E, Bouy jenkov V, Brettler D. Modern treatment of haemophilia. Bull W orld 
Health Organ . 1995; 73:691-701.
17. Iorio A, Marchesini E, Marcucci M, Stobart K, Chan AKC.  Clottin g factor concentrates 
given to prevent bleeding and bleeding -related complications in people with hemophilia 
A or B (Review).  The Cochrane Library .  2011, Issue 9.  
http://www.thecochranelibrary .com
18. Aronstam A, McLellan DS, Wassef M, Mbatha PS.  Effect of height and weight on the 
in vivo recovery  of transfused factor VIII.  J Clin Pathol 1982; 35:[ADDRESS_280333] GE, et al.  Tailored prophy laxis in severe hemophilia A: 
interim resu lts from the first [ADDRESS_280334]. 2006; 4: 1228 -1236.
20. Medical and Scientific Advisory  Council (MASAC).  MASAC Recommendation #117: 
Recommendation concerning prophy laxis (prophylactic administration of clotting factor 
concentrate to prevent bleeding).  May  2001 [cited 2006 April]; Available from: 
http://www.hemophilia.org.
21. Lofqvist T, Nilsson IM, Berntorp E, Pettersson H.  Haemophilia proph ylaxis in y oung 
patients - a long- term follow -up.  J Intern Med. 1997; 241: 395-400.

Moroctocog alfa (AF -CC) 
3082B2 -313-WW –(B1831001) 
Final Amendm ent 
10,02 October 2015
Page 8522. Gooding A.  ReFacto AF:  Bioanaly tical anal ysis in human plasma and human serum in 
support of Wy eth Protocol 3082B2 -311- WW.  Wyeth Research.  RPT [ZIP_CODE].  2008).

Moroctocog alfa (AF -CC) 
3082B2 -313-WW –(B1831001) 
Final Amendm ent 
10,02 October 2015
Page 8640.APPENDICES
Appendix 1.Guidelines for On -Demand Treatment With Moroctocog a lfa(AF-CC)
Guidelines for On -Demand Treatment With Moroctocog alfa (AF -CC), Based on 
Current Recommendations for On -Demand Therapy With the Licensed Product 
Xyntha®
Type of Bleeding Epi[INVESTIGATOR_232236]
(IU/dL or % of normal)Frequency of Doses ( hours)/
Duration of Therap y (days)
Minor
Early hemarthrosis, minor
muscle or oral bleeds.20-[ADDRESS_280335] 1 day, 
depending upon the severity  of 
the bleeding epi[INVESTIGATOR_1865].
Moderate
Bleeding into muscles.
Mild head trauma.
Bleeding into the oral
cavity .30-60 Repeat infusion every  12 to 
24hours for 3 to 4 day s, or 
until adequate local hemostasis 
is achieved.
Major
Gastrointestinal bleeding.
Intracranial, intra -abdominal
or intrathoracic
bleeding.
Fractures.60-100 Repeat infusion every  8 to 
24hours until bleeding is
resolved
